6-K
SECURITIES AND
EXCHANGE COMMISION
Washington, D.C. 20549
FORM 6-K
Report of Foreign
Private Issuer
Pursuant to Rule 13a-16
or 15d-16 of
The Securities Exchange Act
of 1934
March 14, 2005
SCITEX CORPORATION LTD.
(Translation of
registrants name into English)
3 Azrieli Center
Triangular Tower
Tel Aviv, 67023
Israel
(Address of principal
executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
Form 20-F x
Form 40-F o
Indicate
by check mark whether the registrant by furnishing the information contained
in this Form is also furnishing the information to the Commission pursuant to Rule
12g3-2(b) under the Securities and Exchange Act of 1934.
|
Yes o
No x
Attached hereto and incorporated
herein by reference are the Registrants audited consolidated financial statements as
at December 31, 2004 (including report of independent registered public accounting firm).
SIGNATURE
Pursuant to the requirement of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
|
|
SCITEX CORPORATION LTD.
BY: /S/ Yahel Shachar
Yahel Shachar Chief Financial Officer |
March 14, 2005
SCITEX CORPORATION LTD.
2004 CONSOLIDATED
FINANCIAL STATEMENTS
SCITEX CORPORATION LTD.
2004 CONSOLIDATED FINANCIAL
STATEMENTS
TABLE OF CONTENTS
The
amounts are stated in U.S. dollars ($).
REPORT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM
To the shareholders of
SCITEX
CORPORATION LTD.
We have audited the consolidated balance
sheets of Scitex Corporation Ltd. (the Company) and its subsidiaries as of
December 31, 2004 and 2003 and the related consolidated statements of operations,
changes in shareholders equity and cash flows for each of the three years in the
period ended December 31, 2004. These financial statements are the responsibility of
the Companys Board of Directors and management. Our responsibility is to express an
opinion on these financial statements based on our audits.
We did not audit the financial
statements of certain subsidiaries, which statements reflect total assets of $18,550,000
at December 31, 2004, and total revenues of $31,277,000 for the year then ended. We
did not audit the financial statements of certain associated companies, the Companys
investment in which, as reflected in the balance sheets as of December 31, 2004 and 2003
is $124,000 and $3,328,000, respectively, and the Companys share in losses of which
is $1,418,000, $5,637,000 and $4,106,000 in 2004, 2003 and 2002, respectively. Those
financial statements were audited by other independent registered public accounting firms
whose reports thereon have been furnished to us, and our opinion expressed herein, insofar
as it relates to the amounts included for these companies, is based solely on the reports
of the other independent registered public accounting firms.
We conducted our audits in accordance
with standards of the Public Company Accounting Oversight Board (United States of America)
and with auditing standards generally accepted in Israel, including those prescribed by
the Israeli Auditors (Mode of Performance) Regulations, 1973. Those standards require that
we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a test
basis, evidence supporting the amounts and disclosures in the financial statements. An
audit also includes assessing the accounting principles used and significant estimates
made by the Companys Board of Directors and management, as well as evaluating the
overall financial statement presentation. We believe that our audits and the reports of
the other independent registered public accounting firms provide a reasonable basis for
our opinion.
In our opinion, based on our audits
and the reports of the other independent registered public accounting firms, the
consolidated financial statements referred to above present fairly, in all material
respects, the consolidated financial position of the Company and its subsidiaries as of
December 31, 2004 and 2003 and the consolidated results of operations, changes in
shareholders equity and cash flows for each of the three years in the period ended
December 31, 2004, in conformity with accounting principles generally accepted in the
United States of America.
Tel-Aviv, Israel |
|
BY: /S/ Kesselman & Kesselman
Certified Public Accountants (Isr.) |
2
SCITEX CORPORATION LTD.
CONSOLIDATED BALANCE
SHEETS
|
December 31
|
|
2004
|
2003
|
|
U.S. dollars in thousands
|
|
|
|
|
|
|
A s s e t s |
|
|
| |
|
| |
|
CURRENT ASSETS: | | |
Cash and cash equivalents | | |
| 85,892 |
|
| 56,761 |
|
Short-term investments | | |
| 56,693 |
|
| 8,235 |
|
Restricted deposit | | |
| 18,000 |
|
| 18,262 |
|
Trade receivables | | |
| 33,585 |
|
| 31,279 |
|
Other receivables | | |
| 7,369 |
|
| 6,990 |
|
Deferred income taxes | | |
| 758 |
|
| 112 |
|
Inventories | | |
| 36,726 |
|
| 22,575 |
|
Current assets of discontinued operation | | |
| |
|
| 161,602 |
|
|
| |
| |
T o t a l current assets | | |
| 239,023 |
|
| 305,816 |
|
|
| |
| |
INVESTMENTS AND OTHER NON-CURRENT | | |
ASSETS: | | |
Associated companies | | |
| 124 |
|
| 3,328 |
|
Restricted deposit | | |
| 5,000 |
|
| |
|
Other investments and prepaid expenses | | |
| 1,738 |
|
| 1,301 |
|
Funds in respect of employee rights upon retirement | | |
| 3,125 |
|
| 2,040 |
|
|
| |
| |
| | |
| 9,987 |
|
| 6,669 |
|
|
| |
| |
PROPERTY, PLANT AND EQUIPMENT, net of | | |
accumulated depreciation and amortization (note 6) | | |
| 9,147 |
|
| 9,204 |
|
GOODWILL (note 7) | | |
| 6,714 |
|
| 5,217 |
|
OTHER INTANGIBLE ASSETS, net of accumulated amortization (note 8) | | |
| 9,282 |
|
| 18,282 |
|
NON-CURRENT ASSETS OF DISCONTINUED OPERATION | | |
| |
|
| 48,897 |
|
|
| |
| |
| | |
| 274,153 |
|
| 394,085 |
|
|
| |
| |
|
|
BY: /S/ Ami Erel
Chairman of the Board of Directors |
|
|
BY: /S/ Raanan Cohen
Interim President & Chief Executive Officer |
3
|
December 31
|
|
2004
|
2003
|
|
U.S. dollars in thousands
|
|
|
|
|
|
|
Liabilities and shareholders' equity |
|
|
| |
|
| |
|
CURRENT LIABILITIES: | | |
Short-term bank credit | | |
| 30,755 |
|
| 49,251 |
|
Current maturities of long-term loans | | |
| 3,557 |
|
| 2,602 |
|
Trade payables | | |
| 21,877 |
|
| 14,505 |
|
Income taxes payable | | |
| 16,437 |
|
| 29,517 |
|
Accrued and other liabilities | | |
| 23,763 |
|
| 17,949 |
|
Current liabilities related to discontinued operation | | |
| 2,193 |
|
| 31,935 |
|
|
| |
| |
T o t a l current liabilities | | |
| 98,582 |
|
| 145,759 |
|
|
| |
| |
LONG-TERM LIABILITIES: | | |
Loans, net of current maturities: | | |
Banks | | |
| 8,802 |
|
| 6,623 |
|
Other | | |
| 2,540 |
|
| 3,623 |
|
Liability for employee rights upon retirement (note 9) | | |
| 4,178 |
|
| 3,022 |
|
Long-term liabilities related to discontinued operation | | |
| |
|
| 5,431 |
|
|
| |
| |
T o t a l long-term liabilities | | |
| 15,520 |
|
| 18,699 |
|
|
|
|
LONG-TERM LOANS FROM RELATED PARTIES | | |
CONVERTIBLE INTO SHARES OF A SUBSIDIARY | | |
| 1,551 |
|
| 756 |
|
COMMITMENTS AND CONTINGENT LIABILITIES (note 10) | | |
|
| |
| |
T o t a l liabilities | | |
| 115,653 |
|
| 165,214 |
|
|
| |
| |
MINORITY INTEREST | | |
| 4,226 |
|
| 4,173 |
|
|
| |
| |
SHAREHOLDERS' EQUITY (note 11): | | |
Share capital - ordinary shares of NIS 0.12 par value | | |
(authorized: December 31, 2004 and 2003 - | | |
48,000,000 shares; issued and outstanding: | | |
December 31, 2004 and 2003 - 43,467,388 shares) | | |
| 6,205 |
|
| 6,205 |
|
Capital surplus | | |
| 278,812 |
|
| 368,104 |
|
Accumulated other comprehensive loss | | |
| (327 |
) |
| (552 |
) |
Deferred stock compensation | | |
| (517 |
) |
| |
|
Accumulated deficit | | |
| (97,599 |
) |
| (144,852 |
) |
Treasury shares, at cost (December 31, 2004 and 2003 - | | |
5,401,025 shares and 448,975 shares respectively) | | |
| (32,300 |
) |
| (4,207 |
) |
|
| |
| |
T o t a l shareholders' equity | | |
| 154,274 |
|
| 224,698 |
|
|
| |
| |
| | |
| 274,153 |
|
| 394,085 |
|
|
| |
| |
The
accompanying notes are an integral part of the financial statements.
4
SCITEX CORPORATION LTD.
CONSOLIDATED STATEMENTS
OF OPERATIONS
|
Year ended December 31
|
|
2004
|
2003
|
2002
|
|
U.S. dollars in thousands
(except per share data)
|
|
|
|
|
|
|
|
|
REVENUES: |
|
|
| |
|
| |
|
| |
|
Products | | |
| 78,418 |
|
| 60,653 |
|
| 52,847 |
|
Supplies | | |
| 42,186 |
|
| 36,589 |
|
| 27,716 |
|
Services | | |
| 7,581 |
|
| 5,638 |
|
| 5,098 |
|
|
| |
| |
| |
T o t a l revenues | | |
| 128,185 |
|
| 102,880 |
|
| 85,661 |
|
COST OF REVENUES: | | |
Cost of products | | |
| 44,132 |
|
| 36,062 |
|
| 28,336 |
|
Cost of supplies | | |
| 14,759 |
|
| 14,326 |
|
| 10,492 |
|
Cost of services | | |
| 12,176 |
|
| 12,824 |
|
| 12,009 |
|
|
| |
| |
| |
T o t a l cost of revenues | | |
| 71,067 |
|
| 63,212 |
|
| 50,837 |
|
|
| |
| |
| |
GROSS PROFIT | | |
| 57,118 |
|
| 39,668 |
|
| 34,824 |
|
RESEARCH AND DEVELOPMENT COSTS, net | | |
| 12,449 |
|
| 11,070 |
|
| 7,060 |
|
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES | | |
| 36,604 |
|
| 30,469 |
|
| 28,477 |
|
AMORTIZATION OF INTANGIBLE ASSETS | | |
| 6,137 |
|
| 5,871 |
|
| 2,944 |
|
IMPAIRMENT OF OTHER INTANGIBLE ASSETS | | |
| 5,235 |
|
| 2,967 |
|
| |
|
RESTRUCTURING CHARGES | | |
| |
|
| 1,590 |
|
| |
|
|
| |
| |
| |
OPERATING LOSS | | |
| (3,307 |
) |
| (12,299 |
) |
| (3,657 |
) |
FINANCIAL EXPENSES, net | | |
| (276 |
) |
| (2,651 |
) |
| (3,139 |
) |
OTHER INCOME (LOSS), net | | |
| 470 |
|
| 787 |
|
| (26,270 |
) |
|
| |
| |
| |
LOSS BEFORE TAXES ON INCOME | | |
| (3,113 |
) |
| (14,163 |
) |
| (33,066 |
) |
TAXES ON INCOME (note 12) | | |
| 67 |
|
| (2,402 |
) |
| 648 |
|
SHARE IN LOSSES OF ASSOCIATED COMPANIES | | |
| (1,418 |
) |
| (5,637 |
) |
| (4,106 |
) |
MINORITY INTERESTS IN A SUBSIDIARY | | |
| 71 |
|
| 3,546 |
|
| |
|
|
| |
| |
| |
NET LOSS FROM CONTINUING OPERATIONS | | |
| (4,393 |
) |
| (18,656 |
) |
| (36,524 |
) |
NET INCOME FROM DISCONTINUED OPERATION | | |
| 51,646 |
|
| 20,043 |
|
| 4,494 |
|
|
| |
| |
| |
NET INCOME (LOSS) | | |
| 47,253 |
|
| 1,387 |
|
| (32,030 |
) |
|
| |
| |
| |
| | |
| | |
EARNING (LOSS) PER SHARE ("EPS") - BASIC AND DILUTED: | | |
Continuing operations | | |
| (0.11 |
) |
| (0.43 |
) |
| (0.84 |
) |
Discontinued operation | | |
| 1.28 |
|
| 0.46 |
|
| 0.10 |
|
|
| |
| |
| |
| | |
| 1.17 |
|
| 0.03 |
|
| (0.74 |
) |
|
| |
| |
| |
WEIGHTED AVERAGE NUMBER OF SHARES | | |
USED IN COMPUTATION OF EPS (in thousands): | | |
Basic | | |
| 40,336 |
|
| 43,018 |
|
| 43,018 |
|
|
| |
| |
| |
Diluted | | |
| 40,336 |
|
| 43,018 |
|
| 43,018 |
|
|
| |
| |
| |
The
accompanying notes are an integral part of the financial statements.
5
SCITEX CORPORATION LTD.
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY
|
Share
capital
|
Capital
surplus
|
Accumulated
other
comprehensive
Income (loss)
|
Accumulated
deficit
|
Deferred Stock
Compensation
|
Treasury
shares
|
Total
shareholders'
equity
|
|
U.S. d o l l a r s i n t h o u s a n d s
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE AT JANUARY 1, 2002 |
|
|
| 6,205 |
|
| 364,619 |
|
| 7,754 |
|
| (114,209 |
) |
| -,- |
|
| (4,207 |
) |
| 260,162 |
|
CHANGES DURING THE YEAR ENDED DECEMBER 31, 2002: | | |
Net loss | | |
| |
|
| |
|
| |
|
| (32,030 |
) |
| |
|
| |
|
| (32,030 |
) |
Other comprehensive income (loss), net, in respect of: | | |
Currency translation adjustments | | |
| |
|
| |
|
| 189 |
|
| |
|
| |
|
| |
|
| 189 |
|
Available-for-sale securities | | |
| |
|
| |
|
| (7,342 |
) |
| |
|
| |
|
| |
|
| (7,342 |
) |
Derivative instruments designated for cash flow hedge | | |
| |
|
| |
|
| 200 |
|
| |
|
| |
|
| |
|
| 200 |
|
|
| |
| |
| |
| |
| |
| |
| |
Total comprehensive loss | | |
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| (38,983 |
) |
|
| |
| |
| |
| |
| |
| |
| |
BALANCE AT DECEMBER 31, 2002 | | |
| 6,205 |
|
| 364,619 |
|
| 801 |
|
| (146,239 |
) |
| -,- |
|
| (4,207 |
) |
| 221,179 |
|
CHANGES DURING THE YEAR ENDED DECEMBER 31, 2003: | | |
Net Income | | |
| |
|
| |
|
| |
|
| 1,387 |
|
| |
|
| |
|
| 1,387 |
|
Other comprehensive loss, in respect of currency translation adjustments | | |
| |
|
| |
|
| (1,353 |
) |
| |
|
| |
|
| |
|
| (1,353 |
) |
|
| |
| |
| |
| |
| |
| |
| |
Total comprehensive income | | |
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| 34 |
|
|
| |
| |
| |
| |
| |
| |
| |
Share in beneficial conversion feature relating to convertible | | |
preferred shares issued by Scitex Vision (see note 3b) | | |
| |
|
| 3,485 |
|
| |
|
| |
|
| |
|
| |
|
| 3,485 |
|
|
| |
| |
| |
| |
| |
| |
| |
BALANCE AT DECEMBER 31, 2003 | | |
| 6,205 |
|
| 368,104 |
|
| (552 |
) |
| (144,852 |
) |
| -,- |
|
| (4,207 |
) |
| 224,698 |
|
CHANGES DURING THE YEAR ENDED DECEMBER 31, 2004: | | |
Net income | | |
| |
|
| |
|
| |
|
| 47,253 |
|
| |
|
| |
|
| 47,253 |
|
Other comprehensive income, in respect of: | | |
Available-for-sale securities | | |
| |
|
| |
|
| (327 |
) |
| |
|
| |
|
| |
|
| (327 |
) |
Realization of currency translation adjustments | | |
| |
|
| |
|
| 552 |
|
| |
|
| |
|
| |
|
| 552 |
|
|
| |
| |
| |
| |
| |
| |
| |
Total comprehensive income | | |
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| 47,478 |
|
|
| |
| |
| |
| |
| |
| |
| |
Cash distribution | | |
| |
|
| (89,837 |
) |
| |
|
| |
|
| |
|
| |
|
| (89,837 |
) |
Deferred stock compensation related to options granted to employees | | |
| |
|
| 545 |
|
| |
|
| |
|
| (545 |
) |
| |
|
| |
|
Amortization of deferred stock compensation from options granted to employees | | |
| |
|
| |
|
| |
|
| |
|
| 28 |
|
| |
|
| 28 |
|
Treasury shares | | |
| |
|
| |
|
| |
|
| |
|
| |
|
| (28,093 |
) |
| (28,093 |
) |
|
| |
| |
| |
| |
| |
| |
| |
BALANCE AT DECEMBER 31, 2004 | | |
| 6,205 |
|
| 278,812 |
|
| (327 |
) |
| (97,599 |
) |
| (517 |
) |
| (32,300 |
) |
| 154,274 |
|
|
| |
| |
| |
| |
| |
| |
| |
The
accompanying notes are an integral part of the financial statements.
6
(Continued 1)
SCITEX CORPORATION LTD.
CONSOLIDATED STATEMENTS
OF CASH FLOWS
|
Year ended December 31
|
|
2004
|
2003
|
2002
|
|
U.S. dollars in thousands
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM OPERATING ACTIVITIES: |
|
|
| |
|
| |
|
| |
|
Net income (loss) | | |
| 47,253 |
|
| 1,387 |
|
| (32,030 |
) |
Net income from discontinued operation | | |
| (51,646 |
) |
| (20,043 |
) |
| (4,494 |
) |
|
| |
| |
| |
Net loss from continuing operations | | |
| (4,393 |
) |
| (18,656 |
) |
| (36,524 |
) |
Adjustments to reconcile net loss from continuing operations | | |
to net cash provided by (used in) operating activities: | | |
Income and expenses not involving cash flows: | | |
Minority interests in a subsidiary | | |
| (71 |
) |
| (3,546 |
) |
| |
|
Provision for doubtful accounts | | |
| 827 |
|
| 1,233 |
|
| 1,337 |
|
Share in losses of associated companies , net | | |
| 1,418 |
|
| 5,637 |
|
| 4,106 |
|
Depreciation and amortization | | |
| 9,064 |
|
| 9,406 |
|
| 5,194 |
|
Impairment of goodwill and other intangible assets | | |
| 5,625 |
|
| 2,967 |
|
| |
|
Restructuring charges | | |
| |
|
| 291 |
|
| |
|
Loss (gain) on disposal of fixed assets | | |
| 7 |
|
| 321 |
|
| (16 |
) |
Gain from sale of interest in a subsidiary | | |
| |
|
| (3,774 |
) |
| |
|
Share in beneficial conversion feature of convertible | | |
preferred shares issued by a subsidiary | | |
| |
|
| 3,485 |
|
| |
|
Amortization of deferred stock compensation | | |
| 28 |
|
| |
|
| |
|
Settlement in respect of acquired technology | | |
| (390 |
) |
| |
|
| |
|
Gain from issuance of shares by an associated company | | |
| (137 |
) |
| |
|
| |
|
Long-term prepaid expenses | | |
| (324 |
) |
| |
|
| |
|
Write-off and write-down of investments in | | |
investee companies and available-for-sale securities | | |
| 137 |
|
| 2,493 |
|
| 26,122 |
|
Gain from waiver of loan | | |
| (581 |
) |
| |
|
| |
|
Interest on long-term loans | | |
| 272 |
|
| (347 |
) |
| 944 |
|
Revaluation of long-term loan | | |
| |
|
| (408 |
) |
| |
|
Deferred income taxes, net | | |
| (646 |
) |
| 1,754 |
|
| (64 |
) |
Loss (gain) from sale of available-for-sale securities | | |
| 70 |
|
| (11,058 |
) |
| |
|
Changes in operating asset and liability items: | | |
| |
|
| |
|
| |
|
Decrease (Increase) in trade and other receivables | | |
| (3,038 |
) |
| (7,729 |
) |
| (6,581 |
) |
Decrease (increase) in inventories | | |
| (14,977 |
) |
| 112 |
|
| 1,937 |
|
Decrease in accounts payable and accruals | | |
| (301 |
) |
| 4,248 |
|
| (1,394 |
) |
Other items, net | | |
| (154 |
) |
| (8 |
) |
| (254 |
) |
|
| |
| |
| |
Net cash used in continuing operations | | |
| (7,564 |
) |
| (13,579 |
) |
| (5,193 |
) |
Net cash provided by (used in) discontinued operation | | |
| (2,740 |
) |
| 7,415 |
|
| 9,564 |
|
|
| |
| |
| |
Net cash provided by (used in) operating activities | | |
| (10,304 |
) |
| (6,164 |
) |
| 4,371 |
|
|
| |
| |
| |
CASH FLOWS FROM INVESTING ACTIVITIES: | | |
Acquisition of assets and operations consolidated for the first time* | | |
| 294 |
|
| 771 |
|
| (2,181 |
) |
Acquisition of available for sale marketable securities | | |
| (98,198 |
) |
| |
|
| |
|
Proceeds from sale of marketable securities | | |
| 49,034 |
|
| |
|
| |
|
Purchase of fixed assets | | |
| (1,913 |
) |
| (3,306 |
) |
| (10,324 |
) |
Proceeds from sale of fixed assets |
|
|
|
|
|
|
|
|
|
10 |
|
Proceeds from settlement in respect of acquired Technology | | |
| 1,000 |
|
| |
|
| |
|
Proceeds from sale of investment in discontinued operations | | |
| 230,418 |
|
| |
|
| |
|
Proceeds from sale of other investment | | |
| |
|
| 53,886 |
|
| |
|
Purchase of goodwill and intangible assets | | |
| (2,140 |
) |
| (820 |
) |
| (1,012 |
) |
Restricted deposits | | |
| (4,738 |
) |
| 3,427 |
|
| (20,203 |
) |
Investment in associated companies and other investments | | |
| (594 |
) |
| (3,061 |
) |
| (3,466 |
) |
|
| |
| |
| |
Net cash provided by (used in) investing activities | | |
| 173,163 |
|
| 50,897 |
|
| (37,176 |
) |
|
| |
| |
| |
7
(Concluded 2)
SCITEX CORPORATION LTD.
CONSOLIDATED STATEMENTS OF
CASH FLOWS
|
Year ended December 31
|
|
2004
|
2003
|
2002
|
|
U.S. dollars in thousands
|
|
|
|
|
|
|
|
|
Subtotal - brought forward |
|
|
| (162,859 |
) |
| 44,733 |
|
| (32,805 |
) |
|
| |
| |
| |
| | |
CASH FLOWS FROM FINANCING ACTIVITIES: | | |
Receipt of long-term loans | | |
| |
|
| 612 |
|
| 8,000 |
|
Purchase of treasury shares | | |
| (28,093 |
) |
| |
|
| |
|
Cash distribution | | |
| (89,837 |
) |
| |
|
| |
|
Issuance of Convertible long-term loans and warrants to related parties | | |
| 805 |
|
| 933 |
|
| |
|
Repayment of long-term loans and other liabilities | | |
| (3,033 |
) |
| (19,425 |
) |
| (8,759 |
) |
Increase (decrease) in short-term bank credit , net | | |
| (13,570 |
) |
| 8,194 |
|
| 5,287 |
|
|
| |
| |
| |
Net cash provided by (used in) financing activities | | |
| (133,728 |
) |
| (9,686 |
) |
| 4,528 |
|
|
| |
| |
| |
NET INCREASE (DECREASE) IN CASH AND CASH | | |
EQUIVALENTS | | |
| 29,131 |
|
| 35,047 |
|
| (28,277 |
) |
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR | | |
| 56,761 |
|
| 21,714 |
|
| 49,991 |
|
|
| |
| |
| |
CASH AND CASH EQUIVALENTS AT END OF YEAR | | |
| 85,892 |
|
| 56,761 |
|
| 21,714 |
|
|
| |
| |
| |
| | |
* Acquisition of assets and operations consolidated | | |
for the first time: | | |
Assets and liabilities at the date of acquisition: | | |
Deficiency in working capital (excluding cash | | |
and cash equivalents) | | |
| 574 |
|
| 4,754 |
|
| |
|
Fixed assets, net | | |
| (140 |
) |
| (4,447 |
) |
| |
|
Goodwill arising from acquisition | | |
| |
|
| (2,043 |
) |
| |
|
Investment in associated company | | |
| 2,266 |
|
Intangible assets arising from acquisition | | |
| (2,987 |
) |
| (11,376 |
) |
| (2,181 |
) |
Long-term loans and other liabilities | | |
| 581 |
|
| 6,361 |
|
| |
|
Minority interests in subsidiary at date of | | |
acquisition | | |
| |
|
| 7,522 |
|
| |
|
|
| |
| |
| |
Cash received (paid) | | |
| 294 |
|
| 771 |
|
| (2,181 |
) |
|
| |
| |
| |
SUPPLEMENTAL DISCLOSURE OF CASH FLOW | | |
INFORMATION: | | |
Interest paid | | |
| 1,500 |
|
| 4,166 |
|
| 1,703 |
|
|
| |
| |
| |
Income taxes paid | | |
| 13,106 |
|
| 2,652 |
|
| 732 |
|
|
| |
| |
| |
The
accompanying notes are an integral part of the financial statements.
8
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
NOTE 1 GENERAL:
|
Scitex
Corporation Ltd. (the Company) is an Israeli corporation, which through its
subsidiaries operates in two segments: |
|
1) |
Wide
Format digital printing develop, manufacture and market industrial
digital inkjet printing solutions mainly to the graphic arts, packaging
and textile markets as well as related services and consumable products. |
|
2) |
Continuous
inkjet industrial digital printing develop, manufacture and market of
continuous inkjet based digital printers for the industrial printing ceramic
tiles and textile markets. |
|
In
addition, the Company holds minority interest in other companies that develop digital
printing solution to industrial applications and Internet related imaging products.
Amounts provided in these notes to the consolidated financial statements pertain to
continuing operations unless otherwise indicated. |
|
b. |
Sale
of the High-Speed Digital Printing segment |
|
On
November 25, 2003, the Company entered into an agreement according to which it would sell
substantially all of the assets, liabilities and operations of its indirect wholly-owned
subsidiary Scitex Digital Printing Inc. (SDP) related to its High-Speed
Digital Printing Business, including most of the distribution channels that served SDP,
to Eastman Kodak Company (Kodak), for $ 250 million in cash (in addition $12
million were retained at SDP following the transaction). Pursuant to the agreement, a $25
million was held in escrow. $15 million out of the above escrow amount was released in
February 2004 to SDPs parent company (SDC wholly owned
subsidiary) account, and the remaining $10 million would be held in escrow for up to two
years and will be used for indemnification liabilities under the agreement. $5 million
out of the above remaining $10 million escrow, amount was released in January 2005 to SDPs
account The remaining $5M is scheduled to be released in the beginning of 2006, in
accordance with the applicable terms associated thereto. These amounts are presented as
restricted deposit (long and short-term, in equal shares) in the companys balance
sheet as of December 31, 2004. |
|
The
assets, net of liabilities sold are distinguishable as a component of the Company and
classified as Assets or Liabilities of discontinued operation in accordance
with Statement of Financial Accounting Standards No. 144 (SFAS 144), Accounting
for the Impairment on Disposal of Long-Lived Assets of the Financial Accounting
Standards Board of the United States (FASB). |
|
The
closing of the transaction took place on January 5, 2004. As a result of the transaction,
the Company recorded a net gain of approximately $60 million, approximately $52 million
which are included in the statement of operations in 2004, and approximately $8 million
of which were recognized in the fourth quarter of 2003 as a tax benefit related to
expected utilization of carryforward tax losses including capital losses and is recorded
under income from discontinued operation. |
9
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 1 GENERAL
(continued):
|
Operating
results of SDP have been reported in these financial statements as discontinued
operations in accordance with SFAS 144 and the Company has reclassified its results of
operations, and the related assets and liabilities for the prior period in accordance
with provisions of SFAS 144. |
|
1) |
The
assets and liabilities of SDP classified as discontinued operation in the
Consolidated Balance Sheets, are as follows: |
|
December 31
|
|
2004
|
2003
|
|
U.S. dollars in thousands
|
|
|
|
|
|
|
A s s e t s |
|
|
| |
|
| |
|
Current assets: | | |
Cash and Short-term investments | | |
| |
|
| 16,056 |
|
Trade and other receivables | | |
| |
|
| 68,811 |
|
Inventories | | |
| |
|
| 40,506 |
|
Deferred income taxes | | |
| |
|
| 36,229 |
|
|
| |
| |
T o t a l current assets | | |
| |
|
| 161,602 |
|
|
| |
| |
Investment and other non-current assets | | |
| |
|
| 2,040 |
|
Property, plant and equipment, net of accumulated | | |
depreciation and amortization | | |
| |
|
| 26,223 |
|
Goodwill | | |
| |
|
| 19,730 |
|
Other intangible assets, net of accumulated amortization | | |
| |
|
| 904 |
|
|
| |
| |
T o t a l non-current assets | | |
| |
|
| 48,897 |
|
|
| |
| |
T o t a l assets | | |
| |
|
| 210,499 |
|
|
| |
| |
Liabilities | | |
Current liabilities | | |
| 2,193 |
|
| 31,935 |
|
Long-term liabilities: | | |
Deferred income taxes | | |
| |
|
| 3,883 |
|
Other | | |
| |
|
| 1,548 |
|
|
| |
| |
T o t a l Long-term liabilities | | |
| |
|
| 5,431 |
|
|
| |
| |
T o t a l liabilities | | |
| 2,193 |
|
| 37,366 |
|
|
| |
| |
10
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 1 GENERAL
(continued):
|
2) |
Revenues
and net income from the discontinued operations of SDP are as follow: |
|
Year ended December 31
|
|
2003
|
2002
|
|
U.S. dollars in thousands
|
|
|
|
|
|
|
Revenues |
|
|
| 170,113 |
|
| 157,111 |
|
Cost of revenues | | |
| 101,721 |
|
| 98,573 |
|
|
| |
| |
Gross profit | | |
| 68,392 |
|
| 58,538 |
|
Other operation expenses | | |
| 56,300 |
|
| 52,772 |
|
|
| |
| |
Operating income | | |
| 12,092 |
|
| 5,766 |
|
Financial income , net | | |
| 3,970 |
|
| 1,103 |
|
Other expenses , net | | |
| (390 |
) |
| (182 |
) |
|
| |
| |
Income before taxes on income | | |
| 15,672 |
|
| 6,687 |
|
Taxes on income | | |
| (4,371 |
) |
| 2,193 |
|
|
| |
| |
Net income for the year | | |
| 20,043 |
|
| 4,494 |
|
|
| |
| |
|
In
2004 the company recognized a gain of $51,646,000 on the said sale of SDP, see paragraph
b above. |
NOTE 2
SIGNIFICANT ACCOUNTING POLICIES:
|
1) |
Risk
factors and concentration |
|
The
Company and its subsidiaries are subject to various risks, including but not limited to:
(i) business and industry risks like product and technology development; market
acceptance of new products and continuing demand for its products; the impact of
competitive products and pricing; diversification of the business; intellectual property
protection; environmental related liabilities, changes in domestic and foreign economic
and market conditions; and timely development and release of new products by strategic
suppliers; (ii) financial risks such as currency fluctuations, credit risks, obtaining
future financing for affiliated companies, and decreases in the value of our financial
investments; and (iii) risks related to operations in Israel like political, economic and
military instability in Israel or the Middle East; and terms and conditions of tax
benefits and governmental grants. See also note 13 for financial instruments and other
risks. |
11
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 2
SIGNIFICANT ACCOUNTING POLICIES:
|
The
U.S. dollar is the functional currency for the Company and its subsidiaries. The majority
of the sales of the Company are made in US dollars. Since the U.S. dollar is the primary
currency in the economic environment in which the foreign subsidiaries operate, monetary
accounts maintained in currencies other than the U.S. dollar (principally cash and
liabilities) are remeasured using the representative foreign exchange rate at the balance
sheet date. Operational accounts and non monetary balance sheet accounts are measured and
recorded at the rate in effect at the date of the transaction. The effects of foreign
currency remeasurement are reported in current operations and have not been material to
date. |
|
The
financial statements of a former subsidiary classified as discontinued operation
whose functional currency is its local currency, were translated into US dollars
in accordance with the principles set forth in Statement of Financial Accounting
Standards (FAS) No. 52 Foreign Currency Translation. The
resulting aggregate translation adjustments were presented in shareholders equity,
under accumulated other comprehensive income (loss)". |
|
3) |
Use
of estimates in the preparation of financial statements |
|
The
preparation of financial statements in conformity with generally accepted accounting
principles requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at
the dates of the financial statements and the reported amounts of revenues and expenses
during the reporting years. Actual results could differ from those estimates. |
|
The
consolidated financial statements have been prepared in accordance with accounting
principles generally accepted in the United States of America. |
|
b. |
Principles
of consolidation |
|
The
consolidated financial statements include the accounts of the Company and its
subsidiaries. Intercompany balances and transactions have been eliminated in
consolidation. Unrealized profits from intercompany sales have also been eliminated. |
12
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 2 SIGNIFICANT
ACCOUNTING POLICIES (continued):
|
The
Company and its subsidiaries consider all highly liquid investments, with an original
maturity of three months or less at time of investment, that are not restricted as to
withdrawal or use, to be cash equivalents. |
|
d. |
Investments
in marketable securities |
|
The
company classifies its existing marketable equity and debt securities, in accordance with
the provisions of FAS 115 as available-for-sale. Investments in debt securities
classified as available-for-sale are reported at fair value with unrealized gains and
losses, net of related tax, recorded as a separate component of comprehensive income in
shareholders´ equity until realized. Interest and amortization of premiums and
discounts for debt securities and gains and losses on securities sold are included in
financial income. For all investment securities, unrealized losses that are other than
temporary are recognized in net income. The company does not hold these securities for
speculative or trading purposes. |
|
e. |
Other
non-marketable investments |
|
These
investments are carried at cost, net of write-down for decrease in value, which is not of
a temporary nature. |
|
Inventories
are valued at the lower of cost or market. Cost is determined as follows: |
|
Raw-materials
on the moving average basis. |
|
Finished
products and products in process on basis of production costs: |
|
Raw
materials on the moving average basis. Labor and overhead component standard
manufacturing costs. |
|
Inventory
valuation provision is based on specific analysis of inventory items, their aging,
obsolescence, and estimated future demand. |
|
g. |
Investments
in associated companies |
|
Associated
companies are companies over which significant influence is exercised, but which are not
consolidated subsidiaries, and are accounted for by the equity method, net of write-down
for decrease in value, which is not of a temporary nature. The excess of cost of
investment in associated companies over the Companys share in their net assets at
date of acquisition (excess of cost of investment) represents amounts
attributed to know-how and technology. The excess of cost of investment is amortized over
a period of 5 years, commencing in the year of acquisition. |
13
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 2 SIGNIFICANT
ACCOUNTING POLICIES (continued):
|
h. |
Property,
plant and equipment |
|
Property,
plant and equipment are carried at cost and are depreciated by the straight-line method
over their estimated useful life. Annual rates of depreciation are as follows: |
|
%
|
|
|
|
|
|
|
|
|
Machinery and equipment |
Mainly 20 |
Building |
2.5 |
Office furniture and equipment |
Mainly 6 |
Computers |
33 |
|
Leasehold
improvements are amortized by the straight-line method over the term of the lease or the
estimated useful life of the improvements, whichever is shorter. |
|
According
to the provision of FAS No. 142 Goodwill and Other Intangible Assets,
goodwill is no longer being amortized but tested for impairment at least annually. |
|
The
Company has completed its annual goodwill impairment test during the forth quarter of
2004. No impairment of goodwill resulted from the annual review performed in 2004, 2003
and 2002. |
|
j. |
Other
intangible assets |
|
Other
intangible assets which consist mainly of technology are presented at cost and are
amortized by the straight-line method over a period of 5-6 years. These intangible assets
are presented net of impairment in value, see also note 8. |
|
k. |
Impairment
of long-lived assets |
|
FAS
144 Accounting for the Impairment or Disposal of Long-Lived Assets (FAS
144), requires that long-lived assets including certain intangible assets, to be
held and used by an entity be reviewed for impairment whenever events or changes in
circumstances indicate that the carrying amount of the assets may not be recoverable.
Under FAS 144, if the sum of the expected future cash flows (undiscounted and
without interest charges) of the long-lived assets is less than the carrying amount of
such assets, an impairment loss would be recognized, and the assets would be written down
to their estimated fair values. As to impairment of intangible assets, see note 8. |
14
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 2 SIGNIFICANT
ACCOUNTING POLICIES (continued):
|
Deferred
taxes are determined utilizing the asset and liability method based on the estimated
future tax effects of differences between the financial accounting and tax bases of
assets and liabilities under the applicable tax laws. Deferred income tax provisions and
benefits are based on the changes in the deferred tax asset or tax liability from period
to period. Valuation allowances are provided for deferred tax assets when it is more
likely than not that all or a portion of the deferred tax assets will not be realized.
The Company may incur an additional tax liability in the event of an intercompany
dividend distribution by non-Israeli subsidiaries. No additional tax liability has been
provided, since the Company does not intend to distribute, in the foreseeable future,
dividends which would result in an additional tax liability. |
|
Taxes
that would apply in the event of disposal of investments in non-Israeli subsidiaries have
not been taken into account in computing the deferred taxes, as it is the current Companys
intention to hold these investments and not to realize them. |
|
As
stated in note 12a(1)(a), upon distribution of dividends from tax-exempt income of approved
enterprises, the amount distributed will be subject to tax at the rate that would
have been applicable had the Company not been exempted from payment thereof. The amount
of the related tax is charged as an expense in the income statements. The Company intends
to permanently reinvest the amounts of tax-exempt income and does not intend to cause
dividend distribution from such income. Therefore, no deferred taxes have been provided
in respect of such tax-exempt income. |
|
m. |
Comprehensive
income (loss) |
|
In
addition to net income (loss), other comprehensive income (loss) includes unrealized
gains and losses on available-for-sale securities, currency translation adjustments of
non-dollar currency financial statements of a subsidiary and gains and losses on certain
derivative instruments designated for cash-flow hedge and unrealized losses on marketable
securities which are classified as available-for-sale under FAS 115. |
|
Companys
shares held by the Company, are presented as a reduction of shareholders equity, at
their cost to the Company. |
15
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 2 SIGNIFICANT
ACCOUNTING POLICIES (continued):
|
Revenues
from sales of products and supplies are recognized when an arrangement exists, delivery
has occurred and title passed to the customer, the Companys price to the customer
is fixed or determinable and collectability is reasonably assured. With respect to
products with installation requirements, revenue is recognized when all of the above
criteria are met and installation is completed. When sales transactions include more then
one deliverable (unit of accounting) sold, the Company separates the different units of
accounting of sales with multiple deliverables (generally consists of machine and ink)
based on the objective and reliable evidence of fair value of the different elements,
which is estimated based on stand alone sale prices of the different elements and other
reliable evidence that is readily obtainable in the market from competitors, distributors
and others, in accordance with Emerging Issues Task Force (EITF) Issue 00-21,
Revenue Arrangements with Multiple Deliverables. |
|
Sales
contracts with distributors stipulate fixed prices and current payment terms and are not
subject to the distributors resale or any other contingencies. Accordingly when all
criteria above are met, sales of finished products to distributors are recognized as
revenue upon delivery and after title and risk pass to the distributors. |
|
The
Company does not grant any rights of return or cancellation to any of its clients.
Service revenue is recognized ratably over the contractual period or as services are
performed. Warranty costs are provided for at the same time as the revenues are
recognized. The annual provision for warranty costs is calculated based on expected cost
of inputs, based on historical experience. |
|
p. |
Shipping
and handling fees and costs |
|
Amounts
billed to customers for shipping and handling costs are included in revenues in the
statements of operations. Shipping and handling costs are classified as a component of
cost of revenues. |
|
q. |
Research
and development costs, net |
|
Research
and development costs are charged to income as incurred. Royalty-bearing grants received
from governments for approved projects are recognized as a reduction of expenses as the
related costs are incurred. |
16
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 2 SIGNIFICANT
ACCOUNTING POLICIES (continued):
|
These
costs are charged to income as incurred. |
|
s. |
Allowance
for doubtful accounts |
|
The
allowance for doubtful accounts is determined specifically for debts doubtful of
collection. |
|
t. |
Stock
based compensation |
|
The
Company and its subsidiaries account for employee stock based compensation in accordance
with Accounting Principles Board Opinion No. 25 Accounting for Stock Issued to
Employees (APB 25) and related interpretations. Under APB 25
compensation cost for employee stock option plans is measured using the intrinsic value
based method of accounting, and is amortized by the straight-line method against income,
over the expected service period. |
|
FAS
123 Accounting for Stock-Based Compensation, establishes a fair value based
method accounting for employee stock options or similar equity instruments, and
encouraged adoption of such method for stock compensation plans. However, it also allows
companies to continue to account for those plans the accounting treatment prescribed by
APB 25. |
|
Proforma
information regarding net income (loss), required under FAS 123, has been determined as
if the Company and its subsidiaries had accounted for its stock options under the fair
value method of FAS 123. The fair value for their stock options was estimated at the date
of each option grant using the Black-Scholes option pricing model with the following
assumptions: in 2004 for the Company: risk-free interest rate of 3.1%; dividend yields of
zero; expected life of the options of approximately 3 years; and expected volatility of
52%. For a subsidiary for 2004 and 2003: risk-free interest rate of 3.23% to 2.3% and
2.2% respectively; dividend yields of zero in 2004 and 2003; expected life of the options
of approximately 3 years in 2004 and 2003; and expected volatility of 50% to 57% and 48%,
respectively. |
17
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 2 SIGNIFICANT
ACCOUNTING POLICIES (continued):
|
The
following table illustrates the effect on net income (loss) and earning (loss) per share
assuming the Company and its subsidiaries had applied the fair value recognition
provisions of FAS 123 to its stock-based employee compensation: |
|
Year ended December 31
|
|
2004
|
2003
|
2002
|
|
U.S. dollars in thousands (except for per
share data)
|
|
|
|
|
|
|
|
|
Net loss from continuing operations - as reported |
|
|
| (4,393 |
) |
| (18,656 |
) |
| (36,524 |
) |
Add: stock based employee compensation expenses, | | |
included in reported net loss from continuing | | |
Operations (net of minority interest) | | |
| 28 |
|
| -,- |
|
| -,- |
|
Deduct: stock based employee compensation | | |
expenses determined under fair value method | | |
(net of minority interest) | | |
| (593 |
) |
| (1,018 |
) |
| (2,242 |
) |
|
| |
| |
| |
Pro-forma net loss from continuing operations | | |
| (4,958 |
) |
| (19,674 |
) |
| (38,766 |
) |
|
| |
| |
| |
Net income from discontinued operations - as reported | | |
| 51,646 |
|
| 20,043 |
|
| 4,494 |
|
Add: stock based employee compensation expenses, | | |
included in reported net income from discontinued | | |
Operations | | |
| -,- |
|
| -,- |
|
| -,- |
|
Deduct: stock based employee compensation | | |
expenses determined under fair value method | | |
(net of minority interest) | | |
| -,- |
|
| (1,305 |
) |
| (2,109 |
) |
|
| |
| |
| |
Pro-forma net income from discontinued operations | | |
| 51,646 |
|
| 18,738 |
|
| 2,385 |
|
|
| |
| |
| |
Pro-forma net income (loss) | | |
| 46,688 |
|
| (936 |
) |
| (36,381 |
) |
|
| |
| |
| |
Basic and diluted earning (loss) per share - as reported: | | |
Continuing operations | | |
| (0.11 |
) |
| (0.43 |
) |
| (0.84 |
) |
Discontinued operations | | |
| 1.28 |
|
| 0.46 |
|
| 0.10 |
|
|
| |
| |
| |
Net income (loss) | | |
| 1.17 |
|
| 0.03 |
|
| (0.74 |
) |
|
| |
| |
| |
Pro-forma earning (loss) per share : | | |
Continuing operations | | |
| (0.12 |
) |
| (0.46 |
) |
| (0.90 |
) |
Discontinued operations | | |
| 1.28 |
|
| 0.44 |
|
| 0.05 |
|
|
| |
| |
| |
Net income (loss) | | |
| 1.16 |
|
| (0.02 |
) |
| (0.85 |
) |
|
| |
| |
| |
18
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 2 SIGNIFICANT
ACCOUNTING POLICIES (continued):
|
u. |
Earning
(loss) per share (EPS) |
|
Basic
EPS are computed based on the weighted average number of shares outstanding during each
year excluding the treasury shares held by the Company. Diluted EPS reflects the increase
in the weighted average number of shares outstanding that would result from the assumed
exercise of options, calculated using the treasury-stock-method (in 2004, 2003 and 2002
such effect was not included since it would have been anti-dilutive). In addition,
diluted EPS does not reflect options and warrants granted by subsidiaries to be exercised
to the subsidiaries shares and convertible loans, since their effect would have been
immaterial or anti-dilutive. Options exercisable to the Companys ordinary shares
not included in the EPS calculation since their effect is anti-dilutive include options
granted to employees only, see note 11. |
|
v. |
Derivatives
and hedging activities |
|
FAS
133 Accounting for derivative instruments and hedging activities as amended,
establishes accounting and reporting standards for derivatives and for hedging
activities. Under FAS 133, all derivatives are recognized on balance sheet date at their
fair value. On the date that the Company enters into a derivative contract, it designates
the derivative, for accounting purposes, as: (1) an hedging instrument, or (2) a
non-hedging instrument. Changes in the fair value of derivatives that do not qualify for
hedge accounting are recognized in earnings. For the years ended December 31, 2004 and
2003, all derivatives used by the Company did not qualify for hedge accounting and gains
and losses thereon are recorded in financial expenses, net on the Companys
statements of operations. |
|
Certain
comparative figures have been reclassified to conform to the current year presentation. |
|
x. |
Recently
issued accounting pronouncements: |
|
FAS
123 (Revised 2004) Share-based Payment
In
December 2004, the Financial Accounting Standards Board (FASB) issued the
revised Statement of Financial Accounting Standards (FAS) No. 123, Share-Based
Payment (FAS 123R), which addresses the accounting for share-based
payment transactions in which the Company obtains employee services in exchange for (a)
equity instruments of the Company or (b) liabilities that are based on the fair value of
the Companys equity instruments or that may be settled by the issuance of such
equity instruments. This statement eliminates the ability to account for employee
share-based payment transactions using APB Opinion No. 25 and requires instead that such
transactions be accounted for using the grant-date fair value based method. This
statement will be effective as of the beginning of the first interim or annual reporting
period that begins after June 15, 2005 for the company and its subsidiaries. Early
adoption of FAS 123R is encouraged. This Statement applies to all awards granted or
modified after the statements effective date. In addition, compensation cost for
the unvested portion of previously granted awards that remain outstanding on the statements
effective date shall be recognized on or after the effective date, as the related
services are rendered, based on the awards grant-date fair value as previously
calculated for the pro-forma disclosure under FAS 123. |
19
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 2 SIGNIFICANT
ACCOUNTING POLICIES (continued):
|
The
Company estimates that the cumulative effect of adopting FAS 123R as of its adoption date
by the Company and its subsidiaries (July 1, 2005), based on the awards outstanding as of
December 31, 2004, will be immaterial. This estimate does not include the impact of
additional awards, which may be granted, or forfeitures, which may occur subsequent to
December 31, 2004 and prior to the adoption of FAS 123R. The Company expects that
upon the adoption of FAS 123R, the Company will apply the modified prospective
application transition method, as permitted by the statement. Under such transition
method, upon the adoption of FAS 123R, the Companys financial statements for
periods prior to the effective date of the statement will not be restated. The impact of
this statement on the Companys financial statements or its results of operations in
2005 and beyond will depend upon various factors, among them the Companys future
compensation strategy. Currently, The Company expects the effect of the Statement the
Companys financial statements and its results of operations in future periods to be
approximately $100,000 additional expenses per quarter (based on the options as existed
at December 31, 2004). |
|
FAS 151 Inventory
Costs an amendment of ARB 43, Chapter 4
In
November 2004, the FASB issued FAS No. 151, Inventory Costs an Amendment of
ARB 43, Chapter 4 (FAS 151). This statement amends the guidance in ARB
No. 43, Chapter 4, Inventory Pricing, to clarify the accounting for abnormal
amounts of idle facility expense, freight, handling costs, and wasted material. This
statement requires that those items be recognized as current-period charges. In addition,
this Statement requires that allocation of fixed production overheads to the costs of
conversion be based on the normal capacity of the production facilities. This statement
will be effective for inventory costs incurred during fiscal years beginning after June
15, 2005 (January 1, 2006 for the Company). Earlier application of FAS 151 is permitted.
The provisions of this statement shall be applied prospectively. The Company does not
expect this statement to have a material effect on the Companys financial
statements or its results of operations. |
|
FAS
153 Exchanges of Nonmonetary Assets An Amendment of APB Opinion No. 29 In
December 2004, the FASB issued FAS No. 153, Exchanges of Non-Monetary Assets An
Amendment of APB Opinion No. 29 (FAS 153). FAS 153 amends APB
Opinion No. 29, Accounting for Non-Monetary Transactions (Opinion 29).
The amendments made by FAS 153 are based on the principle that exchanges of non-monetary
assets should be measured based on the fair value of the assets exchanged. Further, the
amendments eliminate the exception for non-monetary exchanges of similar productive
assets and replace it with a general exception for exchanges of non-monetary assets that
do not have commercial substance. The provisions in FAS 153 are effective for
non-monetary asset exchanges occurring in fiscal periods beginning after June 15, 2005
(July 1, 2005 for the Company). Early application of the FAS 153 is permitted. The
provisions of this Statement shall be applied prospectively. The Company does not
expect the adoption of FAS 153 to have a material effect on the Companys financial
statements or its results of operations. |
20
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 2 SIGNIFICANT
ACCOUNTING POLICIES (continued):
|
EITF
Issue 03-1, The Meaning of Other-Than-Temporary Impairment and Its Application to Certain
Investments In March 2004, the FASB issued EITF Issue No. 03-1, The
Meaning of Other-Than-Temporary Impairment and Its Application to Certain Investments which
provides new guidance for assessing impairment losses on debt and equity investments.
Additionally, EITF Issue No. 03-1 includes new disclosure requirements for
investments that are deemed to be temporarily impaired. In September 2004, the FASB
delayed the accounting provisions of EITF Issue No. 03-1; however, the disclosure
requirements remain effective and have been adopted by the Company in these financial
statements. The Company will evaluate the effect, if any, of EITF Issue No. 03-1
when final guidance is released. |
|
EITF
Issue 02-14, Whether an Investor Should Apply the Equity Method of Accounting to Investments
Other Than Common Stock In July 2004, the FASB issued EITF Issue No. 02-14,
Whether an Investor Should Apply the Equity Method of Accounting to Investments
Other Than Common Stock. EITF Issue No. 02-14 addresses whether the equity
method of accounting applies when an investor does not have an investment in voting
common stock of an investee but exercises significant influence through other means. EITF
Issue No. 02-14 states that an investor should only apply the equity method of
accounting when it has investments in either common stock or in-substance common stock of
the investee, provided that the investor has the ability to exercise significant
influence over the operating and financial policies of the investee. The provisions in
EITF Issue No. 02-14 are effective for reporting periods beginning after September
15, 2004 (October 1, 2004 for the Company). The adoption of EITF 02-14 by the Company did
not have any effect on the Companys financial statements or its results of
operations. |
NOTE 3
ACQUISITIONS OF BUSINESSES:
|
a. |
Scitex
Vision International Ltd. |
|
On
January 1, 2003, the Company sold all of its shares in its then wholly owned subsidiary
Scitex Vision International Ltd. (then known as Scitex Vision Ltd.) (hereafter
SV international), to Scitex Vision Ltd. (then known as Aprion Digital
Ltd.), the Companys then affiliated company, in exchange for additional preferred
shares in Scitex Vision. Subsequent to the transaction, the Company holds approximately
75% of Scitex Visions outstanding shares. The transaction was accounted for, by the
Company, as a sale of 25% in SV international and as acquisition of additional shares in
Scitex Vision. The fair value of the transaction was approximately $9 million. As a
result, the Company recognized a net capital gain of $289,000 under Other income
(loss), net ($3,774,000 capital gain resulting from the sale of a portion in SV
international, net of $3,485,000 of dilution loss relating to Scitex Visions
preferred shares anti-dilution mechanism triggered by the transaction). In addition, the
Company recognized a capital surplus of $3,485,000 under Beneficial conversion
feature relating to convertible preferred shares issued by Scitex Vision in its
shareholders equity. |
21
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 3 ACQUISITIONS OF
BUSINESSES (continued):
|
This
acquisition was accounted for under the purchase method. As a result of the transaction
the Company recorded technology and goodwill of approximately $14.8 million and
approximately $2 million, respectively, of which approximately $3.8 million was credited
to minority interest. The technology is being amortized over 6 years (as to impairment of
such technology, see note 8) |
|
Commencing
on January 2003 Scitex Visions financial statements are consolidated with those of
the Company. |
|
As
to lawsuits filed in connection with this transaction see note 10b(1). |
|
In
April 2002, SV International acquired some of the assets and operations from Siantec SARL
(Siantec) and its shareholders for a consideration of $2,470,000 (including
transaction expenses), of which $1,860,000 was allocated to technology and $610,000 to a
non-compete covenant. The amount allocated to technology was written down during 2003. In
February 2004, as part of settlement of alleged breaches of representations and
warranties made by Siantec in the asset purchase agreement, Siantec agreed to pay SV
International $1 million out of an escrow account and to waive its rights to existing
contingent payments of up to $10 million. The payment was allocated: $610,000 as a
reversal of the non-compete covenant intangible asset and $390,000 as deduction of
impairment of intangible assets in 2004. |
|
c. |
Techno
Ink Manufacturing (PTY) Ltd. |
|
In
March 2001, SV International acquired the ink technology, other assets and operations
from the Techno Ink Manufacturing (PTY) Ltd. (Techno Ink), for an aggregate
consideration of $2,860,000. The technology is amortized over 6 years. The agreement
provides for additional payments to Techno Ink of up to a maximum of approximately
$5,500,000, based on the achievement of specified financial targets, during the period
from 2001 to 2006 (Earn-Out). As of December 31, 2004, an additional amount
of $3,937,000 has been paid for the Earn-Out and recorded as goodwill ($1,497,000 and
$1,258,000 in the years ended December 31, 2004 and 2003, respectively). |
22
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 4 INVESTMENTS IN
ASSOCIATED COMPANIES (including associated Company consolidated for the first time
in 2004):
|
a. |
Jemtex
ink jet printing Ltd. |
|
In
December 2002, the Company signed a share purchase agreement with Jemtex ink jet printing
Ltd (Jemtex), according to which, the Company invested additional $2,400,000
in three equal quarterly installments of $800,000 each. The first installment and an
advance of $250,000 on the last payment were made in December 2002. The additional
$1,350,000 was transferred in February and May 2003. The excess of cost of investment
over the Companys share in Jemtex net assets at the date of transaction in
the amount of $1,371,000 was attributed to technology to be amortized over five years. |
|
In
addition, Jemtex granted to the Company for no additional consideration, warrants to
purchase (1) 3,181 preferred shares of Jemtex at an exercise price of $ 251.467 per
share, exercisable until January 2, 2004, and (2) 3,181 preferred shares of Jemtex at an
exercise price of $251.467 per share exercisable until March 31, 2005. An amount of
$51,000 was allocated to the said warrants out of the total above-mentioned investment of
$2,400,000. In August 2003, the Company invested in Jemtex an amount of $799,917 by way
of convertible loan, bearing interest at the rate of LIBOR+0.75%. The loan is due on
August 31, 2007, and is convertible at the option of the holder, at any time during the
term of the note and the accrued interest, into preferred shares, at a price a price per
share of $2.51467, and subject to certain adjustments. According to the investment
agreement and upon is execution, the second warrant to purchase 3,181 preferred shares of
Jemtex was cancelled. |
|
In
the beginning of 2004, the Company concluded a $1.5 million investment in Jemtex in
consideration for convertible loans, out of which $0.45 million were provided to Jemtex
in late 2003 and $1.05 million were provided to Jemtex in early 2004. In addition, during
2004, the Company invested an additional amount of $1.9 million by way of convertible
loans. Convertible loans and accrued interest thereon may be converted by Scitex into
preferred shares of Jemtex at any time during a 5-year period at an exercise price
reflecting the estimated fair value of the Companys shares at the date of grant of
the loans. The loans bear interest equivalent to of approximately LIBOR plus 0.75%-1%. In
the beginning of 2005, the Company invested an additional amount of $0.35 million,
substantially under the same terms and conditions of previous convertible loans. |
|
As
of December 31, 2004, the Company effectively holds approximately 84% of Jemtexs
issued share capital on an as-converted basis. Jemtex has a capital deficit
and as the Company is currently the sole financier of Jemtex, it has taken full share
(100%) in Jemtex losses commencing on the third quarter of 2003 and onward. |
|
Since
January 2004, Jemtex financial statements are consolidated with those of the Company,
since the Company effectively has the right to appoint 4 out of 6 directors and holds
majority of the shareholders voting rights. |
|
Share
in losses of associated companies in 2004 includes $294,000 share in losses of Jemtex
prior to its consolidation. |
23
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 4 INVESTMENTS IN
ASSOCIATED COMPANIES (including associated Company consolidated for the first time
in 2004) (continued):
|
The
investment in Objet Geometries Ltd. (Objet) is accounted for under the equity
method. The balance of this investment as of December 31, 2004 is approximately $124,000,
following an additional investment of approximately $ 344,000 made in 2004 as part of a
financing round. As a result of the financing round in 2004 the company interest in Objet
was diluted to 22.9%. |
|
Summarized
data from Objets financial statements for the years ended December 31, 2004 and
2003, is as follows: |
|
December 31,
|
|
2004
|
2003
|
|
Audited
|
Audited
|
|
U.S. dollars in thousands
|
|
|
|
Current assets |
|
|
| 8,515 |
|
| 4,753 |
|
|
| |
| |
Non-current assets | | |
| 1,415 |
|
| 1,482 |
|
|
| |
| |
Current liabilities | | |
| 11,938 |
|
| 9,554 |
|
|
| |
| |
Non-current liabilities | | |
| 732 |
|
| 644 |
|
|
| |
| |
|
Year ended December 31,
|
|
2004
|
2003
|
|
Audited
|
Audited
|
|
U.S. dollars in thousands
|
|
|
|
Revenues |
|
|
| 16,951 |
|
| 4,966 |
|
|
| |
| |
Gross profit | | |
| 6,520 |
|
| 923 |
|
|
| |
| |
Operating income (loss) | | |
| (678 |
) |
| (6,106 |
) |
|
| |
| |
Net income (loss) | | |
| (845 |
) |
| (6,228 |
) |
|
| |
| |
NOTE 5 OTHER
INVESTMENTS AND PREPAID EXPENSES:
|
Other
investments represent investments in non-marketable securities in companies operating in
the digital printing and digital imaging industry, in which the Company does not exercise
significant influence, and which are stated at cost, net of a write-down for decrease in
value which is not of a temporary nature. The carrying amounts of these investments as of
December 31, 2004 and 2003 are $1,414,000 and $1,301,000, respectively. The company
evaluated these carrying values for impairment as of those dates. In 2004, there was no
impairment in value. In 2003, due to an extended decline in fair value of other than
temporary nature, the Company recorded an accumulated loss in the amount of $2,493,000
that was charged to other income (loss), net in the statement of operations.
In addition, other investments include as of December 31, 2004, $324,000 of
long-term prepaid expenses. |
24
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 6 PROPERTY,
PLANT AND EQUIPMENT
|
Grouped
by major classifications, the assets are composed as follows: |
|
December 31
|
|
2004
|
2003
|
|
U.S. dollars in thousands
|
|
|
|
|
|
|
Machinery and equipment |
|
|
| 7,218 |
|
| 4,567 |
|
Building | | |
| 465 |
|
| 424 |
|
Leasehold improvements | | |
| 5,309 |
|
| 4,606 |
|
Office furniture and equipment | | |
| 7,321 |
|
| 5,209 |
|
Motor vehicles | | |
| 31 |
|
| 16 |
|
|
| |
| |
| | |
| 20,344 |
|
| 14,822 |
|
Less - accumulated depreciation | | |
and amortization | | |
| (11,197 |
) |
| (5,618 |
) |
|
| |
| |
| | |
| 9,147 |
|
| 9,204 |
|
|
| |
| |
|
Depreciation
and amortization of property, plant and equipment from continuing operations totaled
$2,927,000, $3,558,000 and $2,250,000 in 2004, 2003 and 2002, respectively. |
NOTE 7 GOODWILL
|
The
changes in the carrying amount of goodwill in respect of the continuing operations for
the years ended December 31, 2003 and 2004, are as follows: |
|
U.S. dollars
in thousands
|
|
|
|
|
|
|
|
|
Balance as of January 1, 2003 |
|
|
| 2,171 |
|
Goodwill acquired | | |
| 3,046 |
|
|
| |
Balance as of December 31, 2003 | | |
| 5,217 |
|
Goodwill acquired, see note 3c | | |
| 1,497 |
|
|
| |
Balance as of December 31, 2004 | | |
| 6,714 |
|
|
| |
25
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 8 OTHER INTANGIBLE
ASSETS:
|
Grouped
by major classifications, the acquired technology and other intangible assets are
composed as follows: |
|
December 31
|
|
2004
|
2003
|
|
U.S. dollars
in thousands
|
|
|
|
|
|
|
Gross carrying amount: |
|
|
| |
|
| |
|
Acquired technology | | |
| 53,553 |
|
| 47,361 |
|
Other intangible assets | | |
| 550 |
|
| 878 |
|
|
| |
| |
| | |
| 54,103 |
|
| 48,239 |
|
|
| |
| |
L e s s - accumulated amortization and | | |
impairment charges: | | |
Acquired technology | | |
| 44,770 |
|
| 29,957 |
|
Other intangible assets | | |
| 51 |
|
|
| |
| |
| | |
| 44,821 |
|
| 29,957 |
|
|
| |
| |
| | |
| 9,282 |
|
| 18,282 |
|
|
| |
| |
|
Amortization
expenses totaled $6,137,000, $5,871,000, and $2,944,000 in 2004, 2003 and 2002,
respectively. |
|
As
to the main additions to intangible assets, see notes 3 and 4. |
|
Estimated
amortization expense for the following years, subsequent to December 31, 2004: |
|
U.S. dollars
in thousands
|
|
|
|
|
|
|
|
|
Year ending December 31: |
|
|
| |
|
2005 | | |
| 4,446 |
|
2006 | | |
| 2,914 |
|
2007 | | |
| 1,671 |
|
2008 | | |
| 117 |
|
2009 | | |
| 117 |
|
2010 | | |
| 17 |
|
|
| |
| | |
| 9,282 |
|
|
| |
|
In
2004 and 2003 the financial statements include an impairment charge with respect to
technology and know-how in a subsidiary, in the amounts of $5,625,000 and $2,967,000,
respectively. These impairments followed an evaluation performed by a third party
appraiser, based on discounted cash flow, triggered by the significant decrease in the
production of certain products based on the above-mentioned technologies. The impairment
calculation in 2004 and 2003 was prepared in accordance with the provisions of FAS 144.
Out of the amount of impairment in 2004, $2.6 million was recorded against the minority
interests in a subsidiary since this amount is the amortized technology held by
minority shareholders of Scitex Vision, see note 3a. |
26
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 9 EMPLOYEE
RIGHTS UPON RETIREMENT:
|
a. |
Israeli
labor laws and agreements require the payment of severance pay upon dismissal
of an employee or upon termination of employment in certain other
circumstances. The liability is based upon the length of service and the latest
monthly salary (one months salary for each year worked), and is mainly
funded with severance pay and pension funds and with insurance companies
(principally with an affiliate of the two major shareholders of the Company),
for which the Company and its Israeli subsidiaries make monthly payments. |
|
The
Company records the long-term obligation as if it was payable at each balance sheet date
on an undiscounted basis. |
|
b. |
The
U.S. subsidiaries offer 401(k) matching plans to all eligible employees. |
|
c. |
Substantially
all of the European subsidiaries make contributions to pension plans
administered by insurance companies. |
|
d. |
Severance
pay and defined contribution plan expenses totaled $760,000, $1,523,000 and
$563,000 in 2004, 2003 and 2002, respectively. |
|
e. |
The
Company expects to pay the following future benefits to its Israeli employees
upon their retirement at normal retirement age: |
|
U.S. dollars
in thousands
|
|
|
|
|
|
|
|
|
Year ending December 31: |
|
|
| |
|
2005 | | |
| 12 |
|
2006 | | |
| 10 |
|
2007 | | |
| 39 |
|
2010 | | |
| 100 |
|
2013 | | |
| 145 |
|
|
The
above amounts were determined based on recent salary rates and do not include amounts
that might be paid to employees that will cease working with the company, before their
normal retirement age or amounts to be paid to employees that their normal retirement age
extends beyond the year 2014. |
27
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 10
COMMITMENTS AND CONTINGENT LIABILITIES:
|
1) |
The
Company and its subsidiaries is committed to pay royalties of 3%-5% to the Government of
Israel on sales of products in the research and development of which the Government
participates by way of grants, up to the amount of the grants received (dollar linked),
plus annual interest based on the Libor, accruing from January 1, 1999. At the time the
funding was received, successful development of the related projects was not assured. In
the case of failure of a project that was partly financed by royalty-bearing grants, the
Company is not obligated to pay any such royalties to the Israeli Government. |
|
At
December 31, 2004, the maximum contingent royalty payable is approximately $3.8 million.
Royalty expenses totaled $245,000, $128,000 and $167,000 in 2004, 2003 and 2002,
respectively. |
|
2) |
The
Company is obligated to pay royalties to certain parties, based on agreements
that allow it to use technologies developed by these parties. Such royalties
are based on the revenues from sales of products, which incorporate these
technologies or on quantities of such products sold. Royalty expenses totaled
$1,316,000, $984,000 and $0 in 2004, 2003 and 2002, respectively. |
|
Most
of the premises occupied by the Company and its subsidiaries are rented under various
operating lease agreements. Part of the premises in Israel were leased from an affiliate
of the two major shareholders of the Company. |
|
Minimum
lease payments of the Company and its subsidiaries under the above leases, at rates in
effect on December 31, 2004, are as follows: |
|
U.S. dollars
in thousands
|
|
|
|
|
|
|
|
|
Year ending December 31: |
|
|
| |
|
2005 | | |
| 2,452 |
|
2006 | | |
| 2,132 |
|
2007 | | |
| 1,851 |
|
2008 | | |
| 1,579 |
|
2009 | | |
| 1,579 |
|
2010 and thereafter | | |
| 7,452 |
|
|
Most
of the rental payments for the Israeli premises are payable in Israeli currency,
partially linked to the Israeli CPI, to the dollar or both to the dollar and the U.S.
CPI. Rental expense relating to continuing operations totaled $2,425,000, $2,449,000 and
$1,158,000 in 2004, 2003 and 2002, respectively. |
28
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 10 COMMITMENTS AND
CONTINGENT LIABILITIES (continued):
|
4) |
Commencing
November 1, 2001 and until January 2004, the Companys headquarters
are located on the premises of one of its major shareholders. The Company
obtained the services of certain executives and other staff as well as certain
services from the major shareholder, for which the Company pays amounts based
on formulas determined in the agreement between the Company and the
shareholder. During the first two quarters of 2004, the Companys
headquarters are located on the premises of other major shareholder. The
Company obtains the services of an executive as well as certain ancillary
services from the shareholder, for which the Company pays amounts based on
formulas determined in the agreement between the Company and the shareholder.
Expenses due to the said agreements totaled $227,000, $518,000 and $445,000 in
2004, 2003 and 2002, respectively. Beginning of the third quarter of 2004 the
Company has a lease agreement with an unrelated third party. |
|
b. |
Contingent
liabilities: |
|
1) |
In
October 2003, a NIS 14 million (approximately $3.2 million) lawsuit was filed
by a minority shareholder of a subsidiarys shareholders, against the
Company, a subsidiary and others, mainly other shareholders of the subsidiary
(among them, the Companys two largest shareholders, Clal and Discount)
and the directors of the subsidiary in the period relevant for the lawsuit
(three of whom are our present or former office holders). The lawsuit generally
alleges that the terms of the transaction to combine the operations of the
subsidiary and the subsidiary International and the manner in which it was
effected prejudiced the rights of the minority shareholder as a minority
shareholder of the subsidiary. |
|
In
November 2003, the minority shareholder also sent a demand letter to the subsidiary, as a
preliminary step for a derivative action, whereby the minority shareholder demanded that
the subsidiary initiate a lawsuit against the Company, a company wholly-owned by the
Subsidiary (Subsidiary International) and the subsidiarys directors in
the period relevant for the claim for an alleged breach of fiduciary duties of the
directors and misrepresentations in connection with an undertaking by Scitex to transfer
$15 million to Subsidiary International as part of the aforesaid transaction. |
|
In
December 2003, a separate motion was filed by the minority shareholder against the
Company, the subsidiary, and the two shareholders mentioned above, in connection with the
subsidiarys rights offering that was concluded in July 2003. In particular, the
motion alleges that the reorganization of the subsidiarys share capital that was
effected in conjunction with the rights offering was invalid and prejudiced the rights of
the minority shareholder. In light of its allegations, the minority shareholder requested
that the court order the defendants to provide information and documents with respect to
this matter. |
29
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 10 COMMITMENTS AND
CONTINGENT LIABILITIES (continued):
|
In
May 2004, the minority shareholder filed another lawsuit against the Company, the
subsidiary, and the two shareholders mentioned above in connection with the subsidiarys
rights offering that was concluded in May 2004. The lawsuit generally alleges that the
terms of the transaction and the manner in which it was effected prejudiced the rights of
the minority shareholder as a minority shareholder of the subsidiary. The minority
shareholder requested the court to order that the resolutions of the subsidiarys
audit committee, board of directors and general meeting of shareholders authorizing the
transaction be annulled, and that the transaction is void. |
|
All
parties to the legal proceedings described above agreed to try to settle all of the
disputes between them by mediation and the mediation proceedings are in advance stages.
Therefore, all court proceedings were postponed until March 8, 2005. However, the Company
and the subsidiary rejected the claims and at this stage in time, it is not possible to
predict the outcome of this particular matter. No provision was recorded for this matter
in these financial statements. |
|
2) |
In
January 2003 SV International has received a letter from the legal advisors of
a service provider claiming compensation in the amount of approximately
4,000,000 New Israeli Shekel (NIS) (approximately $928,000) arising
from SV Internationals decision to cease using the service providers
services. The letter of demand alleges that SV International has a contractual
relationship with this service provider. The Company is unable to assess the
outcome of this matter, and SV International intends to mount a vigorous
defense. No provision was recorded in respect of this matter in these financial
statements. |
|
3) |
In
July 2000 a monetary claim in the amount of approximately $413,000 against the
Company was filed with the district court in Jerusalem. In this lawsuit it was
claimed that a machine the Company sold to the plaintiff did not function as
promised by the Company. In April 2000, the Company sold substantially all of
the assets, liabilities and operations related to its Digital PrePrint business
to Creo. Therefore, defense is being handled by Creo. In the opinion of the
Companys management, since this lawsuit is in the framework of an
indemnification agreement with Creo, it will have minimal effect on the
Company, if any. Therefore no provision was recorded for this matter. |
30
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 10 COMMITMENTS AND
CONTINGENT LIABILITIES (continued):
|
4) |
In
December 2003, three minority shareholders of Objet, a company in which
the Company has a 22.91% interest, filed an approximate 7.8 million New
Israeli Shekels (NIS) (approximately $1.75 million)
lawsuit against Objet, certain of its shareholders, including the Company, and
certain of Objets directors. The lawsuit alleges that the defendants
acted in a manner that prejudiced the rights of the minority shareholders, and
breached Objets obligations to such shareholders. Among the remedies
being sought by the said minority shareholders are compensation, restitution
(with linkage and interest) of the investment amount, or repurchase of the
plaintiffs shares in Objet, and a demand for changes to the terms of
certain convertible loans made to Objet by certain of the defendants including
the Company. Objet has asked for a dismissal of the case relating to one of the
parties suing. At this time the Companys attorneys are still evaluating
the claim, and neither Objet nor the Company is able to give any realistic
assessment as to the outcome of this matter, therefore no provision was
recorded. |
|
5) |
Claims
have been filed against the Company and its subsidiaries in the ordinary course
of business. The Company and its subsidiaries intend to defend themselves
vigorously against those claims. Management does not expect that the Company
will incur substantial expenses in respect thereof; therefore, no provision has
been made for the claims. |
|
6) |
As
to tax assessments of two of the Companys subsidiaries, see note 12h. |
NOTE 11
SHAREHOLDERS EQUITY:
|
1) |
The
Companys shares are traded on NASDAQ, under the symbol SCIX, and on The
Tel Aviv Stock Exchange (TASE). |
|
On
December 31, 2004, the Companys share closed on NASDAQ and TASE at $5.21 and
approximately $5.14, respectively. |
|
2) |
The
number of shares stated as issued and outstanding 43,467,388 shares at
December 31, 2004 and 2003 includes, at December 31, 2004 and
December 31, 2003, 5,401,025 shares and 448,975 shares, respectively,
repurchased by the Company and held by the Company or by a trustee. These
shares bear no voting rights or rights to cash dividends. |
31
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 11 SHAREHOLDERS EQUITY
(continued):
|
b. |
Cash
distribution and treasury stock |
|
In
2004, approximately $118 million were transferred by the Company to its shareholders
through a repurchase of shares from the shareholders and a cash distribution: |
|
1) |
In
June 2004, the Company completed a self tender offer and purchased 4,952,050
shares for an aggregate amount of approximately $28.1 million that represent
$5.67 per share. |
|
2) |
In
July 2004, the Company distributed in cash $2.36 per ordinary share, or
approximately $89.8 million in the aggregate, to its shareholders. |
|
Dividends
are declared and paid in dollars (except to shareholders of record with an address in
Israel, with respect to whom payment is made in Israeli currency (NIS)). |
|
d. |
Share
incentive and stock option plans |
|
In
December 2001, the Companys shareholders approved the adoption of the Scitex 2001
Stock Option Plan (2001 Plan), designed primarily for employees and directors
of the Company and its subsidiaries. In December 2003, the Companys shareholders
approved the adoption of the Scitex 2003 Share Option Plan (2003 Plan),
designed for employees, directors and consultants of the Company who are Israeli
residents, and also approved an increase in the aggregate number of shares reserved for
issuance under the 2001 Plan from an initial 750,000 shares to 1,900,000 shares, with all
such reserved shares being available for issuance under either the 2001 Plan or the 2003
Plan. Option awards may be granted under the 2001 Plan until November 5, 2011 and
under the 2003 Plan until November 23, 2013. Terms of the options granted under the
plans, such as length of term, exercise price, vesting and exercisability, are determined
by our board of directors. The maximum term of an option may not exceed ten years. Each
option can be exercised to purchase one share having the same rights as other ordinary
shares of the Company. |
|
The
2003 Plan is designed to be governed by the terms stipulated by Section 102 of the
Israeli Income Tax Ordinance. Inter alia, these terms provide that the Company will be
allowed to claim, as an expense for tax purposes, the amounts credited to the employees
as a benefit in respect of shares or options granted under the plan. The amount allowed
as an expense for tax purposes, at the time the employee utilizes such benefit, is
limited to the amount of the benefit that is liable to tax as labor income, in the hands
of the employee; all being subject to the restrictions specified in Section 102 of the
Income Tax Ordinance. |
|
In
the years ended December 31, 2003 and 2002, no options had been granted under either the
2001 plan or 2003 plan. |
32
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 11 SHAREHOLDERS EQUITY
(continued):
|
On
September 20, 2004, the board of directors resolved to grant two senior employees of the
Company options under the 2003 Plan to purchase an aggregate of 168,000 shares of the
Company at an exercised price of $3.70 per share. The fair value of one share at the day
of grant was $4.11. The options vest ratably over three years and are exercisable for ten
years until September 20, 2014. Any options not exercised by then will expire. In
the year 2004, the Company recorded $69,000 of deferred stock compensation for the excess
of the fair value of shares over the exercise price at the date of grant related to these
options. The deferred stock compensation is amortized over the vesting period using the
straight-line method. The compensation costs of $7,000 have been classified under general
and administrative expenses in 2004. |
|
The
options granted under the Companys plans are exercisable for the purchase of shares
as follows: |
|
December 31
|
|
2004
|
2003
|
|
Number of options
|
|
|
|
|
|
|
At balance sheet date |
|
|
| 351,922 |
|
| 978,732 |
|
During the first year thereafter | | |
| 56,000 |
|
| 8,334 |
|
During the second year thereafter | | |
| 112,000 |
|
|
| |
| |
| | |
| 519,922 |
|
| 987,066 |
|
|
| |
| |
|
A
summary of the status of the Companys plans at December 31, 2004, 2003 and
2002, and changes during the years ended on those dates, is presented below: |
|
Year ended December 31
|
|
2004
|
2003
|
2002
|
|
Number
|
Weighted
average
exercise
price
|
Number
|
Weighted
average
exercise
price
|
Number
|
Weighted
average
exercise
price
|
|
|
$
|
|
$
|
|
$
|
|
|
|
|
|
|
|
Options outstanding at |
|
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
beginning of year | | |
| 987,066 |
|
| 10.48 |
|
| 1,252,492 |
|
| 10.34 |
|
| 1,724,203 |
|
| 10.18 |
|
Changes during the year: | | |
Granted | | |
| 168,000 |
|
| 3.70 |
|
| |
|
| |
|
| |
|
| |
|
Forfeited and canceled | | |
| (635,144 |
) |
| 10.64 |
|
| (265,426 |
) |
| 9.82 |
|
| (471,711 |
) |
| 9.76 |
|
|
| |
| |
| |
| |
| |
| |
Options outstanding at end of year | | |
| 519,922 |
|
| 8.09 |
|
| 987,066 |
|
| 10.48 |
|
| 1,252,492 |
|
| 10.34 |
|
|
| |
| |
| |
| |
| |
| |
Options exercisable at end of year | | |
| 351,922 |
|
| 10.19 |
|
| 978,732 |
|
| 10.50 |
|
| 1,139,728 |
|
| 10.33 |
|
|
| |
| |
| |
| |
| |
| |
Options available for future awards | | |
| 1,732,000 |
|
| |
|
| 1,900,000 |
|
| |
|
| 750,000 |
|
| |
|
|
| |
| |
| |
| |
| |
| |
|
The
weighted average fair value of options granted during 2004 is $1.69. |
|
The
fair value of each option grant is estimated on the date of grant using the Black-Scholes
option-pricing model with the following weighted average assumptions: risk-free interest
rate of 3.1%; dividend yields of zero; expected life of the options of approximately
three years; and expected volatility of 52%. |
33
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 11 SHAREHOLDERS EQUITY
(continued):
|
The
following table summarizes information about options under the Companys plans
outstanding at December 31, 2004: |
Options outstanding
|
Options exercisable
|
Range of exercise prices
|
Number outstanding at December 31, 2004
|
Weighted average remaining contractual life
|
Weighted average exercise price
|
Number exercisable at December 31, 2004
|
Weighted average exercise price
|
$
|
|
Years
|
$
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.70 |
|
| 168,000 |
|
| 9.7 |
|
| 3.70 |
|
| - |
|
| - |
|
| 9.00 to 9.99 |
|
| 145,005 |
|
| 1.6 |
|
| 9.06 |
|
| 145,005 |
|
| 9.06 |
|
| 10.00 to 10.99 |
|
| 100,417 |
|
| 5.1 |
|
| 10.57 |
|
| 100,417 |
|
| 10.57 |
|
| 11.00 to 11.99 |
|
| 90,500 |
|
| 2.3 |
|
| 11.21 |
|
| 90,500 |
|
| 11.21 |
|
| 12.00 to 12.99 |
|
| 16,000 |
|
| 2.3 |
|
| 12.21 |
|
| 16,000 |
|
| 12.21 |
|
|
| |
| |
| |
| |
| |
| |
|
| 519,922 |
|
| 5.1 |
|
| 8.09 |
|
| 351,922 |
|
| 10.19 |
|
|
| |
| |
| |
| |
| |
|
An
award in 1999, whereby 50 % of 300,000 options awarded in earlier years to a related
party, with an exercise price of $14.75 per option, were re-priced to an exercise price
of $11.69 per option (the then market price per share), accompanied by a waiver of the
remaining 50%. Such options were exercisable from 1999 until canceled in June 2004. The
fair value of each option granted was $3.21. In accordance with FIN 44, the re-priced
options are accounted for under variable plan accounting. Under this method of
accounting, increases in the fair market value of the underlying shares result in
stock-based compensation charges to the statement of operations. In June 2004, and on
December 31, 2003, the market price of the underlying shares was below $11.69 (the
exercise price of the options), thus, no compensation cost has been charged with respect
to these options. |
|
Option
plan in a subsidiary |
|
In
September 2003, the board of directors of an Israeli subsidiary approved an employee
stock option plan (the subsidiary plan), whereunder options to purchase up to
12,985,630 ordinary shares of the subsidiary are to be granted to employees, directors
and consultants of the subsidiary without consideration. Each option can be exercised to
purchase one ordinary share of NIS 0.01 par value of the subsidiary. Immediately upon
exercise, the ordinary shares purchased in exercise of the options will have the same
rights as of the subsidiarys other ordinary shares. Any option not exercised within
10 years from allotment date will expire, unless extended by the board of directors of
the subsidiary. |
|
On
December 20, 2004, the subsidiarys board of directors decided to increase the
number of shares reserved under the subsidiary plan with additional options to purchase
up to 5,068,570 ordinary shares. |
|
At
December 31, 2004 and December 31, 2003, there were approximately 17,732,000 and
12,531,000 options, respectively, outstanding subject to the subsidiary plan, of which
8,320,000 and 6,079,265, respectively, were exercisable. |
34
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 11 SHAREHOLDERS EQUITY
(continued):
|
Except
for 193,874 options granted at an exercise price of $4.00 per share, all options were
granted at an exercise price of $0.4052. For all grants, management determined that the
exercise price per share is not less than the estimated fair value of an ordinary share
at the date of grant, except for 4,351,360 options granted in late 2004 whereby
management estimated the fair value of one share to be $0.55. In the year 2004 the
subsidiary recorded $476,000 of deferred stock compensation for the excess of the fair
value of ordinary shares of the subsidiary over the exercise price at the date of grant
related to these options (net of minority interests). The deferred stock compensation is
amortized over the vesting period using the straight-line method. The compensation costs
of $21,000 have been classified to the income statements, under general and
administrative expenses in the year 2004. |
|
The
weighted fair value of options granted by the subsidiary during 2004 and 2003 was $0.24
and $0.14, respectively and estimated at the date of each option grant using the
Black-Scholes option pricing model with the following assumptions: risk-free interest
rate of 3.23% to 2.3% and 2.2% respectively; dividend yields of zero in 2004 and 2003;
expected life of the options of approximately three years in both 2004 and 2003; and
expected volatility of 50% to 57% and 48%, respectively. |
|
During
2004 and 2003, no options were exercised. |
NOTE 12 TAXES ON
INCOME:
|
a. |
The
Company and its Israeli subsidiary: |
|
1) |
Tax
benefits under the Israeli Law for the Encouragement of Capital Investments,
1959 (hereafter- the law) |
|
The
entitlement to these benefits is conditional upon the subsidiary fulfilling the
conditions stipulated by the law, regulations published thereunder and the instruments of
approval for the specific investments in approved enterprises. In the event of failure to
comply with these conditions, the benefits may be cancelled and the subsidiary may be
required to refund the amount of the benefits, in whole or in part, with the addition of
CPI linkage increments and interest. Currently, the subsidiary is in discussions with the
relevant authorities on the rights and entitlement to the below benefits, and the
entitlement of these benefits is conditioned upon the results of these discussions. |
35
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 12 TAXES ON INCOME
(continued):
|
Tax
benefits for approved enterprises include: |
|
The
tax benefit period is seven years from the year in which such an enterprise first earns
taxable income, but not later than 2009. Income derived from the approved enterprise is
tax exempt during the first two years of the seven years tax benefit period and is
subject to a reduced tax rate of 25% during the remaining five benefit years. |
|
In
the event of distribution of cash dividends from income that was tax exempt as above, the
Company would have to pay the 25% tax in respect of the amount distributed. The Company
intends to reinvest the amounts of tax exempt income in the foreseeable future, and not
to cause distribution of such dividends. |
|
b) |
Accelerated
depreciation |
|
The
subsidiary is entitled to claim accelerated depreciation for five tax years, commencing
in the first year of operation of each asset, in respect of machinery and equipment used
by the approved enterprise. |
|
2) |
Measurement
of results for tax purposes under the Income Tax (Inflationary Adjustments)
Law, 1985 (hereafter the Inflationary Adjustments Law) |
|
Under
this law, results for tax purposes are measured in real terms, in accordance with the
changes in the Israeli CPI, or in the exchange rate of the dollar for a foreign
investors company. The Company and its Israeli subsidiaries elected to
measure their results on the basis of the changes in the Israeli CPI. |
|
The
income of the company and its Israeli subsidiaries (other than income from approved
enterprises, see b. below) is taxed at the regular rate. Through to December 31,
2004, the corporate tax was 36%. In July 2004, an amendment to the Income Tax Ordinance
was enacted. One of the provisions of this amendment is that the corporate tax rate is to
be gradually reduced from 36% to 30%, in the following manner: the rate for 2004 will be
35%, in 2005 34%, in 2006 32%, and in 2007 and thereafter 30%. The
effect of the change in the tax rates in the coming years, on the deferred tax balances
of the amendment to the law, is included in paragraph f below. Capital gains are taxed of
25%. |
|
b. |
Non-Israeli
subsidiaries |
|
The
non-Israeli subsidiaries are taxed under the laws of their countries of residence. |
36
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 12 TAXES ON INCOME
(continued):
|
c. |
Carryforward
tax losses and deductions |
|
Carryforward
tax losses and deductions of the Company and its subsidiaries, including capital losses
and losses from realization of marketable securities approximated $466 million at December 31,
2004. Most of the carryforward amounts are available indefinitely with no expiration date. |
|
d. |
Deferred
income taxes: |
|
December 31
|
|
2004
|
2003
|
|
U.S. dollars in thousands
|
|
|
|
|
|
|
Computed in respect of the following: |
|
|
| |
|
| |
|
Allowance for doubtful accounts and | | |
other provisions | | |
| 1,756 |
|
| 1,512 |
|
Carryforward tax losses and credits | | |
| 147,542 |
|
| 168,620 |
|
Inventories | | |
| |
|
| 1,440 |
|
Investments | | |
| 7,244 |
|
| 9,364 |
|
Marketable Securities | | |
| 710 |
|
| |
|
Accrued liabilities and deferred income | | |
| 2,363 |
|
| 1,173 |
|
Property, plant and equipment | | |
| 48 |
|
| 60 |
|
Intangible assets | | |
| 4,020 |
|
| 2,927 |
|
|
| |
| |
| | |
| 163,683 |
|
| 185,096 |
|
L e s s - valuation allowance (attributed | | |
mainly to loss carryforwards and expenses | | |
deductible upon payment) | | |
| (162,925 |
) |
| (184,984 |
) |
|
| |
| |
| | |
| 758 |
|
| 112 |
|
|
| |
| |
Deferred income taxes are included in the | | |
balance sheets in current assets: | | |
| 758 |
|
| 112 |
|
|
| |
| |
|
e. |
Income
(loss) before taxes on income from continuing operation: |
|
Year ended December 31
|
|
2004
|
2003
|
2002
|
|
U.S. dollars in thousands
|
|
|
|
|
|
|
|
|
The Company and its Israeli subsidiaries |
|
|
| (7,599 |
) |
| (15,702 |
) |
| (29,198 |
) |
Non-Israeli subsidiaries | | |
| 4,486 |
|
| 1,539 |
|
| (3,868 |
) |
|
| |
| |
| |
| | |
| (3,113 |
) |
| (14,163 |
) |
| (33,066 |
) |
|
| |
| |
| |
37
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 12 TAXES ON INCOME
(continued):
|
f. |
Taxes
on income included in the statements of operations from continuing
operation: |
|
Year ended December 31
|
|
2004
|
2003
|
2002
|
|
U.S. dollars in thousands
|
|
|
|
|
|
|
|
|
Current: |
|
|
| |
|
| |
|
| |
|
Israeli | | |
| |
|
| 404 |
|
| (400 |
) |
Non-Israeli | | |
| (577 |
) |
| (1,052 |
) |
| 984 |
|
|
| |
| |
| |
| | |
| (577 |
) |
| (648 |
) |
| 584 |
|
|
| |
| |
| |
Deferred, see e. above: | | |
Israeli | | |
| |
|
| (1,866 |
) |
| 64 |
|
Non-Israeli | | |
| 644 |
|
| 112 |
|
| |
|
|
| |
| |
| |
| | |
| 644 |
|
| (1,754 |
) |
| 64 |
|
|
| |
| |
| |
| | |
| 67 |
|
| (2,402 |
) |
| 648 |
|
|
| |
| |
| |
|
2) |
Following
is a reconciliation of the theoretical tax expense, assuming all income is
taxed at the regular tax rate applicable to Israeli corporations (see a(3)
above) and the actual tax expense: |
|
Year ended December 31
|
|
2004
|
2003
|
2002
|
|
U.S. dollars in thousands
|
|
|
|
|
|
|
|
|
Income (loss) before taxes on income |
|
|
| (3,113 |
) |
| (14,163 |
) |
| (33,066 |
) |
|
| |
| |
| |
Theoretical tax expense (tax benefit) on | | |
the above amount | | |
| 1,090 |
|
| (5,099 |
) |
| (11,904 |
) |
Effect of lower tax rate for | | |
"approved enterprises" | | |
| - |
|
| - |
|
| (400 |
) |
|
| |
| |
| |
| | |
| 1,090 |
|
| (5,099 |
) |
| (12,304 |
) |
Increase (decrease) in taxes resulting from | | |
different tax rates - net | | |
| (183 |
) |
| (6,670 |
) |
| (5,253 |
) |
Increase in taxes resulting from | | |
permanent differences | | |
| 1,836 |
|
| 838 |
|
| 408 |
|
Change in valuation allowance | | |
| (22,059 |
) |
| 61,731 |
|
| 87,602 |
|
Changes in deferred taxes resulting from | | |
carryforward tax losses | | |
| 21,413 |
|
| (49,970 |
) |
| (71,275 |
) |
Increase in taxes resulting from prior years | | |
| (515 |
) |
| 1,950 |
|
| |
|
Increase (decrease) in taxes arising | | |
from differences between non-dollar | | |
currencies income and dollar | | |
income , net, and other* | | |
| (1,515 |
) |
| (378 |
) |
| 174 |
|
|
| |
| |
| |
Taxes on income in the consolidated | | |
statements of operations | | |
| 67 |
|
| 2,402 |
|
| (648 |
) |
|
| |
| |
| |
|
* |
Resulting
mainly from the difference between the changes in the Israeli CPI (the basis for
computation of taxable income of the Company and its Israeli subsidiaries, see a(2)
above) and the changes in the exchange rate of Israeli currency relative to the dollar. |
38
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 12 TAXES ON INCOME
(continued):
|
1) |
The
Company has received, or is considered to have receive, final tax assessments
through the 1999 tax year. |
|
2) |
Following
the filing of tax returns of the Companys U.S. subsidiaries for the
years 1992 through 1996 (and receive certain refunds in respect thereof),
the Internal Revenue Service (IRS) commenced an audit on those years. By
the end of 2001, the Company had already made advance payments of $21.5
million on account of this audit. In partial settlement of said audit the
Company consented to a partial assessment by the IRS for
approximately $10.6 million of federal taxes on certain agreed upon issues
in June 2002. In the same month, the Company received a notice from the
IRS proposing to assess $29.6 million of additional federal income taxes
for the years 1992 through 1996. In August 2002, the Company appealed the
proposed additional assessment. In February 2004, following negotiations
with the IRS, the Company finalized the settlement with the IRS, and the
during the remainder of 2004, the Company concluded paying according to
the settlement with the IRS in an amount of $5.9 million to the IRS, and
also paid $5.7 million as state taxes derived from that IRS audit. |
|
3) |
In
December 2004, as a result of the conclusion of the 1992-1996 IRS audit, the
Company filed federal tax amendments for the years 1994, 1995 and 1997,
claiming a refund of $7.8 million of federal taxes. As of the date of
these financial statements, the IRS has not responded to our refund
request. Due to the existing uncertainty surrounding the outcome of this
refund request, the said amount is not included in the financial
statements. |
NOTE 13 FINANCIAL
INSTRUMENTS AND RISK MANAGEMENT:
|
a. |
Foreign
exchange risk management |
|
The
Company and its subsidiaries operate internationally, which gives rise to significant
exposure to market risks, mainly from changes in foreign exchange rates. Derivative
financial instruments (hereafter derivatives) were utilized by a subsidiary to
reduce these risks. The Company did not hold or issue derivative financial instruments
for trading purposes. |
|
Commencing
2003, a subsidiary purchases forward-exchange contracts as hedges of certain anticipated
sales and related costs denominated in foreign currencies. The subsidiary enters into
these contracts to protect itself against the risk that the eventual dollar-net-cash
inflows resulting from direct-foreign-export sales and related costs will be affected by
changes in exchange rates. These contracts do not qualify for hedge accounting under FAS
133. Accordingly gains and losses for these forward-exchange contracts are recognized in
earnings. As of December 31, 2004 and 2003, the liability for losses deriving from
forward-exchange contracts amounted to approximately $412,000 and $556,000, respectively. |
39
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 13 FINANCIAL
INSTRUMENTS AND RISK MANAGEMENT:
|
b. |
Concentrations
of credit risks |
|
At
December 31, 2004 and 2003, the Company and its subsidiaries held cash and cash
equivalents, most of which were deposited with major Israeli, European and U.S. banks.
Substantially, all of the marketable securities held by the Company are debt securities
of the U.S. Treasury and highly rated corporations. The Company considers the inherent
credit risks to be remote. |
|
Most
of the subsidiaries sales are made in the United States, Latin America, Europe and
in the Far East, to a large number of customers. Consequently, the exposure to
concentrations of credit risks relating to individual customer receivables is limited.
The subsidiary performs ongoing credit evaluations of its customers and generally does
not require collateral; however, with respect of certain sales to customers in emerging
economies, the subsidiary requires letters of credit. |
|
c. |
Cash
Management and Fair value of financial instruments |
|
The
financial instruments of the Company and its subsidiaries consist mainly of cash and cash
equivalents, marketable securities, short-term investments, long-term investments,
current and long-term liabilities. |
|
In
view of their nature, the fair value of the financial instruments included in working
capital is usually identical or close to their carrying amount. The fair value of
long-term liabilities also approximates their carrying value, since they bear interest at
rates close to the prevailing market rates. |
40
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 14
SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION:
|
a. |
Short-Term
Investments: |
|
1) |
The
fair value and the amortized cost of available-for-sale securities and cash
equivalents are as follows: |
|
December 31, 2004
|
|
Cost
|
Unrealized
holding
losses (*)
|
Estimated
fair market
value
|
|
U.S. dollars in thousands
|
|
|
|
|
|
|
|
|
United States government and government |
|
|
| |
|
| |
|
| |
|
agencies debentures | | |
| 6,286 |
|
| (53 |
) |
| 6,233 |
|
Corporate debt securities | | |
| 10,672 |
|
| (113 |
) |
| 10,559 |
|
Mortgage backed securities | | |
| 40,062 |
|
| (161 |
) |
| 39,901 |
|
|
| |
| |
| |
| | |
| 57,020 |
|
| (327 |
) |
| 56,693 |
|
|
| |
| |
| |
(*) |
Suchunrealized
holding losses are the result of an increase in market interest rates during fiscal 2004
and are not the result of credit or principal risk. Based on the nature of the
investments, management concluded that such unrealized losses were not other than
temporary as of December 31, 2004. Amounts reclassified out of accumulated comprehensive
income into earning are determined by specific identification. |
|
Maturities
of the above securities are as follows: |
|
Estimated fair
market value
|
|
U.S. dollars
in thousands
|
|
|
|
|
|
|
2005 |
|
|
| 3,567 |
|
2006 | | |
| 16,054 |
|
2007 | | |
| 22,897 |
|
2008 | | |
| 2,999 |
|
2009 and there after | | |
| 11,176 |
|
|
| |
| | |
| 56,693 |
|
|
| |
|
As
of December 31, 2004, the Company held investments in available for sale with unrealized
holding losses totaling $327,000, all of which are less then one year. Realized losses in
2004 were approximately $70,000. |
41
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 14 SUPPLEMENTARY
FINANCIAL STATEMENT INFORMATION (continued):
|
In
June and August 2003, the Company sold all of its remaining holdings in Creo Inc.
(hereafter Creo) shares for a net total consideration of $54,000,000
and recorded a gain of approximately $3,000,000. The investment in Creo shares was
accounted for as shares available for sale, and following the sale of the shares, the
Company recorded approximately $750,000 gain in its shareholders equity. This gain
was realized and released to earnings in 2003. In 2002, due to extended decline in fair
market value, it was determined that the impairment in value of the investment was other
than temporary. Consequently, the accumulated unrealized loss of $22,283,000 was charged
to other income (loss), net in the statement of operation. |
|
December 31
|
|
2004
|
2003
|
|
U.S. dollars in thousands
|
|
|
|
|
|
|
b. Allowance for doubtful accounts (as included |
|
|
| |
|
| |
|
in trade receivables) - the change in allowance | | |
for doubtful is composed as follows: | | |
Balance at beginning of year | | |
| 4,190 |
|
| 2,957 |
|
Addition to allowance | | |
| 1,361 |
|
| 1,233 |
|
Write-off of bad debts | | |
| (534 |
) |
| |
|
|
| |
| |
| | |
| 5,017 |
|
| 4,190 |
|
|
| |
| |
| | |
c. Other receivables: | | |
Value added taxes receivable | | |
| 3,343 |
|
| 3,285 |
|
Employees | | |
| 267 |
|
| 298 |
|
Other | | |
| 3,759 |
|
| 3,407 |
|
|
| |
| |
| | |
| 7,369 |
|
| 6,990 |
|
|
| |
| |
| | |
d. Inventories | | |
Components of systems and materials | | |
| 12,880 |
|
| 8,158 |
|
Work in process | | |
| 843 |
|
| 1,183 |
|
Consumables | | |
| 4,937 |
|
| 5,026 |
|
Finished products | | |
| 18,066 |
|
| 8,208 |
|
|
| |
| |
| | |
| 36,726 |
|
| 22,575 |
|
|
| |
| |
42
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 14 SUPPLEMENTARY
FINANCIAL STATEMENT INFORMATION (continued):
|
e. |
Accrued
and other liabilities: |
|
December 31
|
|
2004
|
2003
|
|
U.S. dollars in thousands
|
|
|
|
|
|
|
Payroll and related expenses |
|
|
| 4,852 |
|
| 3,863 |
|
Accrued royalties and sales commissions | | |
| 1,792 |
|
| 2,514 |
|
Deferred revenue | | |
| 6,361 |
|
| 585 |
|
Provision for warranty* | | |
| 2,151 |
|
| 2,293 |
|
Advances from customers | | |
| 4,089 |
|
| 2,516 |
|
Other | | |
| 4,518 |
|
| 6,178 |
|
|
| |
| |
| | |
| 23,763 |
|
| 17,949 |
|
|
| |
| |
|
2004
|
2003
|
2002
|
|
U.S. dollars in thousands
|
|
|
|
|
|
|
|
|
|
|
|
|
* The changes in the balance during the year: |
|
|
| |
|
| |
|
| |
|
Balance at beginning of the year | | |
| 2,293 |
|
| 2,018 |
|
| 2,577 |
|
Payments made under the warranty | | |
| (4,162 |
) |
| (3,383 |
) |
| (3,136 |
) |
Product warranties issued for new sales | | |
| 4,020 |
|
| 3,658 |
|
| 2,577 |
|
|
| |
| |
| |
Balance at end of year | | |
| 2,151 |
|
| 2,293 |
|
| 2,018 |
|
|
| |
| |
| |
|
f. |
Short-term
credit and long-term loans: |
|
1) |
Short-term
credit and loans |
|
The
balance as of December 31, 2004 represents: $16,397,000 short-term bank loans denominated
in dollars and bearing interest of three months Libor + 1% to Libor + 2.25% per annum (as
of December 31, 2004 and 2003 3.63% to 4.88% and 2.3%-3.5%, respectively);
$14,358,000 short-term bank loans denominated in Euro and bearing interest of Libor +
1.75% to 2% per annum (as of December 31, 2004 and 2003 respectively, 4%- 4.25% and
3.8%-4.4%), current maturities of long term loans from banks in the amount of $2,347,000
and current maturities of other long term loan in the amount of $1,210,000. |
43
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 14 SUPPLEMENTARY
FINANCIAL STATEMENT INFORMATION (continued):
|
2) |
Current
maturities of long-term loans (represent loans of Scitex Vision): |
|
December 31
|
|
2004
|
2003
|
|
U.S. dollars in thousands
|
|
|
|
|
|
|
Banks |
|
|
| 2,347 |
|
| 1,633 |
|
Other | | |
| 1,210 |
|
| 969 |
|
|
| |
| |
| | |
| 3,557 |
|
| 2,602 |
|
|
| |
| |
|
a) |
The
long-term loans from banks mature in the following years: |
|
December 31
|
|
2004
|
2003
|
|
U.S. dollars in thousands
|
|
|
|
|
|
|
Current maturities |
|
|
| 2,347 |
|
| 1,633 |
|
|
| |
| |
Second year | | |
| 2,347 |
|
| 1,928 |
|
Third year | | |
| 2,347 |
|
| 1,252 |
|
Fourth year | | |
| 2,347 |
|
| 1,252 |
|
Fifth year and thereafter | | |
| 1,761 |
|
| 2,191 |
|
|
| |
| |
| | |
| 8,802 |
|
| 6,623 |
|
|
| |
| |
| | |
| 11,149 |
|
| 8,256 |
|
|
| |
| |
|
As
to the maturity dates of another loan see c below. |
|
b) |
The
long-term loans from banks are dollar denominated and bear interest of three
month Libor + 1.75 % to Libor + 2.25 % per annum (as of December 31, 2004 and
2003 4.38% to 4.88 % and 2.9% to 3.4% respectively). |
|
c) |
In
2000, Scitex Vision entered into a collaboration agreement (the Collaboration
Agreement) with a leading European supplier (the supplier) to
the textile, paper and plastics printing industry, for developing inks for
printing on textile. Pursuant to the Collaboration Agreement, the Supplier is
to pay Scitex Vision certain royalties on sales of ink for use with the Scitex
Visions textile printing machines. Following the Collaboration Agreement,
the Company received from the supplier a long-term convertible loan of $5
million. The loan was received on December 27, 2000, and bore 6% annual
interest. However, if the milestones described in the Collaboration Agreement
were met, the loan was to be interest free. |
44
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 14 SUPPLEMENTARY
FINANCIAL STATEMENT INFORMATION (continued):
|
According
to the original terms of the loan, the loan and the accumulated interest may be converted
by the supplier, at any time during the last three months of the loan period, which ends
on December 11, 2003, into ordinary shares of Scitex Vision at a conversion price based
on the fair value of such shares, less 15%. According to the Collaboration Agreement if
the Supplier chooses to request the repayment of the loan, the repayment shall be made by
setting-off the loan and any interest accrued thereon against royalties due to Scitex
Vision in a subsequent period. The remainder of the loan, if any, shall be repaid in cash
to the Supplier. Pursuant to the conversion terms, whereby the Supplier was granted
beneficial conversion features, the Company recorded an original discount of $882,353,
which represents the difference between the loan amount and the value of the ordinary
shares. This amount was fully amortized to interest expense over 33 months, which is the
period from the grant date to the beginning of the period during which the supplier was
entitled to convert the loan into ordinary shares. |
|
On
December 30, 2003 an addendum to the agreement was signed, according to which, the
original terms of the loan were changed such that the principal of the loan ($5 million)
is interest free and payable in four annual installments in the following years
subsequent to December 31, 2003. The first payment of $1 million was paid in December
2004 and the remaining amount is payable as follows (the amounts are presented in their
net present values): |
|
December 31,
2004
|
|
U.S. dollars
in thousands
|
|
|
|
|
|
|
Current maturities |
|
|
| 1,210 |
|
|
| |
Second year | | |
| 1,406 |
|
Third year | | |
| 1,134 |
|
|
| |
| | |
| 2,540 |
|
|
| |
| | |
| 3,750 |
|
|
| |
|
Scitex
Vision has the right to offset royalties due to Scitex Vision against the amount due on
the next agreed installment. As a result of the above-mentioned change in terms, Scitex
Vision has recorded the loan based on its present value using 3.3% interest rate, which
is applicable to such loans as of the date of the change in terms. The difference between
the present value and the nominal value of the loan, in the total amount of $408,000 (Discount),
as well as all interest accrued at December 30, 2003, in the total amount of $904,000,
have been credited to financial expenses, net in the year ended December 31,
2003. The amortization of the Discount recorded as financial expenses, amounted to
$158,000 in 2004. |
45
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 14 SUPPLEMENTARY
FINANCIAL STATEMENT INFORMATION (continued):
|
d) |
Long-term
loans convertible into subsidiarys shares |
|
In
July 2003 and May 2004, two of the Companys shareholders granted Scitex Vision
convertible loans in the total amount of $933,000 and $805,000, respectively, bearing
interest equal to the greater of Libor + 1% (as of December 31, 2004 and 2003 -3.63% and
2.1%, respectively) or the NIS equivalent of the principal amount linked to the rate of
change of the Israeli CPI over the period of the loans. The loans and interest are
payable in one installment at the end of a five year period if no conversion occurs
before the end of the repayment period. The loans may be converted by the lenders to
4,234,316 ordinary shares of the Scitex Vision at any time at an exercise price of
$0.4052 per share, which equals the estimated fair value of Scitex Visions ordinary
shares at the date of grant of the loans. According to the loans agreements, an automatic
conversion shall occur upon the occurrence of certain events. In addition, all lenders
were granted warrants representing 25% of the total loan amount, to purchase 1,058,578
ordinary shares of Scitex Vision at an exercise price of $0.4052 per share. $98,500 and
$54,500 were allocated to the said warrants out of the total above-mentioned loans in
2004 and 2003, respectively. These amounts are amortized to interest expenses over the
maximum term of the loans, which is 5 years. |
|
Pursuant
to the conversion terms, whereby the lenders were granted beneficial conversion features (BCF),
the Company recorded an original discount of $98,500 and $54,500 in 2004 and 2003,
respectively, which represents the difference between the loan allocated amount and the
amount payable. These amounts are amortized to interest expenses over the maximum term of
the loans, which is 5 years. The warrants expire after 5 years from grant as well. |
|
For
the years 2004 and 2003 the Company recorded interest expenses of $99,000 and $20,000,
respectively, in connection with the said warrants, amortization of the BCF amount and
interest expenses. |
|
e) |
Long-term
loans other |
|
In
July 2004, Jemtex received a waiver of all rights regarding a long-term loan at the
amount of $581,000. The waiver of the loan is presented in the financial statements under
other income (loss)". |
46
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 14 SUPPLEMENTARY
FINANCIAL STATEMENT INFORMATION (continued):
|
Statements
of operations: |
|
Year ended December 31
|
|
2004
|
2003
|
2002
|
|
U.S. dollars in thousands
|
|
|
|
|
|
|
|
|
g. Research and development costs , net: |
|
|
| |
|
| |
|
| |
|
Expenses incurred | | |
| 13,043 |
|
| 11,537 |
|
| 7,761 |
|
L e s s - royalty-bearing | | |
participations from the | | |
Government of Israel | | |
| 594 |
|
| 467 |
|
| 701 |
|
|
| |
| |
| |
| | |
| 12,449 |
|
| 11,070 |
|
| 7,060 |
|
|
| |
| |
| |
h. Selling, general and administrative | | |
expenses: | | |
Selling* | | |
| 19,990 |
|
| 15,322 |
|
| 14,896 |
|
General and administrative** | | |
| 16,614 |
|
| 15,147 |
|
| 13,581 |
|
|
| |
| |
| |
| | |
| 36,604 |
|
| 30,469 |
|
| 28,477 |
|
|
| |
| |
| |
* Including: | | |
Advertising costs | | |
| 1,416 |
|
| 609 |
|
| 420 |
|
|
| |
| |
| |
** Including: | | |
Related parties | | |
| 380 |
|
| 518 |
|
| 445 |
|
|
| |
| |
| |
Net change in allowance for | | |
doubtful accounts and direct | | |
write-off of bad debts | | |
| 827 |
|
| 1,233 |
|
| 1,507 |
|
|
| |
| |
| |
|
During
2003, a subsidiary implemented a restructuring plan in the form of reduction in work
force, abandonment of leased premises and development of new combined information
technology system, and accrued expenses accordingly. The expenses included mainly
severance pay and other benefits to approximately 42 employees retiring from their employ
in the amount of approximately $130,000, costs related to the disposal of certain
activities in the amount of approximately $390,000, and costs related to the development
of new combined information technology system in the amount of approximately $500,000. |
47
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 14 SUPPLEMENTARY
FINANCIAL STATEMENT INFORMATION (continued):
|
Year ended December 31
|
|
2004
|
2003
|
2002
|
|
U.S. dollars in thousands
|
|
|
|
|
|
|
|
|
j. Financial expenses, net: |
|
|
| |
|
| |
|
| |
|
Interest income | | |
| 2,874 |
|
| 249 |
|
| 706 |
|
Gain (loss) on trading marketable securities, net | | |
| (70 |
) |
| 3 |
|
| |
|
Interest expense on long-term loans | | |
from banks | | |
| (1,541 |
) |
| (1,981 |
) |
| (2,471 |
) |
from others | | |
| (158 |
) |
| 603 |
|
| |
|
Convertible loan -BCF and warrant | | |
amortization and interests | | |
| (99 |
) |
| (20 |
) |
| |
|
Bank charges | | |
| (427 |
) |
| (276 |
) |
| (15 |
) |
Revaluation of long-term loan | | |
| |
|
| 408 |
|
| |
|
Other (including foreign exchange | | |
transaction losses , net) | | |
| (855 |
) |
| (1,637 |
) |
| (1,359 |
) |
|
| |
| |
| |
| | |
| (276 |
) |
| (2,651 |
) |
| (3,139 |
) |
|
| |
| |
| |
k. Other income (loss), net: | | |
Write-down of available-for-sale securities | | |
| |
|
| |
|
| (22,283 |
) |
Gain from sale of a portion in a subsidiary | | |
| |
|
| 3,774 |
|
| |
|
Share in beneficial conversion feature of | | |
convertible preferred shares issued by a | | |
subsidiary | | |
| |
|
| (3,485 |
) |
| |
|
Write-off and write-down of investments | | |
in investee companies | | |
| (137 |
) |
| (2,493 |
) |
| (3,839 |
) |
Gain from sale of investments in | | |
associated and investee companies | | |
| |
|
| 2,822 |
|
| |
|
Gain from waiver of a loan | | |
| 581 |
|
| |
|
| |
|
Other | | |
| 26 |
|
| 169 |
|
| (148 |
) |
|
| |
| |
| |
| | |
| 470 |
|
| 787 |
|
| (26,270 |
) |
|
| |
| |
| |
NOTE 15 SEGMENTS
INFORMATION:
|
Following
the transaction and as a result of the consolidation of Jemtex for the first time in 2004
the Company operates in the following two segments: |
|
1) |
Wide
Format digital printing development, manufacturing and market
industrial digital inkjet printing solutions mainly to the graphic
arts, packaging and textile markets as well as related services and
consumable products. |
|
2) |
Continuous
inkjet industrial digital printing develop, manufacture and market
of continuous inkjet based digital printers for the industrial printing
ceramic tiles and textile markets. |
48
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 15 SEGMENTS
INFORMATION (continued):
|
b. |
Information
on segment loss and assets of the reportable operating segments: |
|
1) |
Measurement
of segment loss and assets: |
|
The
measurement of losses and assets of the reportable segments is based on the same
accounting principles applied in these consolidated financial statements. |
|
2) |
Financial
data relating to the reportable operating segments: |
|
Year ended
December 31,
2004
|
|
U.S. dollars
in thousands
|
|
|
|
|
|
|
Consolidated revenues from the |
|
|
| |
|
Wide Format digital printing | | |
| 128,185 |
|
|
| |
Operating loss from continuing operations: | | |
Wide Format digital printing | | |
| (532 |
) |
Continuous inkjet industrial digital printing | | |
| (2,775 |
) |
|
| |
Total consolidated operating loss from continuing operations | | |
| (3,307 |
) |
|
| |
| | |
Interest income (expenses), net: | | |
Wide Format digital printing | | |
| (180 |
) |
Continuous inkjet industrial digital printing | | |
| (96 |
) |
|
| |
Total consolidation interest expenses, net | | |
| (276 |
) |
|
| |
| | |
Other income (loss), net: | | |
Wide Format digital printing | | |
| (116 |
) |
Continuous inkjet industrial digital printing | | |
| 586 |
|
|
| |
Total consolidation other income (loss), net | | |
| 470 |
|
|
| |
| | |
Loss before taxes on income: | | |
Wide Format digital printing | | |
| (828 |
) |
Continuous inkjet industrial digital printing | | |
| (2,285 |
) |
|
| |
Total consolidation loss before taxes on income | | |
| (3,113 |
) |
|
| |
49
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 15 SEGMENTS
INFORMATION (continued):
|
December 31,
2004
|
|
U.S. dollars
in thousands
|
|
|
|
|
|
|
Assets: |
|
|
| |
|
Wide Format digital printing: | | |
Intangible assets | | |
| 9,282 |
|
Other assets | | |
| 261,178 |
|
Goodwill | | |
| 6,714 |
|
Continuous inkjet industrial digital printing | | |
| 1,277 |
|
|
| |
| | |
| 278,451 |
|
|
| |
Consolidation adjustment | | |
| (4,298 |
) |
|
| |
| | |
| 274,153 |
|
|
| |
Expenditures for long-lived assets: | | |
Wide Format digital printing: | | |
Intangible assets | | |
| 400 |
|
Fixed assets | | |
| 1,903 |
|
Goodwill | | |
| 1,497 |
|
Continuous inkjet industrial digital printing, other assets | | |
| 10 |
|
|
| |
| | |
| 3,810 |
|
|
| |
| | |
Depreciation and amortization expenses: | | |
Wide Format digital printing: | | |
Intangible assets | | |
| 6,137 |
|
Other assets | | |
| 2,876 |
|
Continuous inkjet industrial digital printing, other assets | | |
| 51 |
|
|
| |
| | |
| 9,064 |
|
|
| |
|
c. |
Geographical
information: |
|
1) |
Following
are data regarding revenues from external customers in respect of continuing
operations, classified by geographical area based on the location of the
customers (Wide Format digital printing segment only): |
|
Year ended December 31
|
|
2004
|
2003
|
2002
|
|
U.S. dollars in thousands
|
|
|
|
|
|
|
|
|
America |
|
|
| 46,070 |
|
| 34,828 |
|
| 26,539 |
|
Europe | | |
| 52,344 |
|
| 36,893 |
|
| 37,504 |
|
Far East | | |
| 19,943 |
|
| 12,460 |
|
| 16,647 |
|
Other countries | | |
| 9,828 |
|
| 18,699 |
|
| 4,971 |
|
|
| |
| |
| |
| | |
| 128,185 |
|
| 102,880 |
|
| 85,661 |
|
|
| |
| |
| |
50
SCITEX CORPORATION LTD.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS (continued)
NOTE 15 SEGMENTS
INFORMATION (continued):
|
2) |
Following
are data relating to property, plant and equipment, net, relating to continuing
operations, by geographical area in which the assets are located: |
|
December 31
|
|
2004
|
2003
|
2002
|
|
U.S. dollars in thousands
|
|
|
|
|
|
|
|
|
Israel |
|
|
| 5,520 |
|
| 6,154 |
|
| 2,985 |
|
America | | |
| 620 |
|
| 802 |
|
| 1,033 |
|
Europe | | |
| 1,112 |
|
| 1,152 |
|
| 753 |
|
South Africa | | |
| 1,534 |
|
| 949 |
|
| 1,265 |
|
Asia | | |
| 361 |
|
| 147 |
|
| 38 |
|
|
| |
| |
| |
| | |
| 9,147 |
|
| 9,204 |
|
| 6,074 |
|
|
| |
| |
| |
51